A retrospective study evaluating the patterns of primary glomerular disease at Charlotte Maxeke Johannesburg academic hospital by Patchapen, Yvette
	 	 	
  
A RETROSPECTIVE STUDY EVALUATING THE 
PATTERNS OF PRIMARY GLOMERULAR DISEASE AT 
CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC 
HOSPITAL 
 
 
 
 
Dr Yvette Patchapen   MBBCh (Wits) FCP (SA) 
 
 
 
A research report submitted to the Faculty of Health Sciences, 
University of the Witwatersrand, in fulfillment of the requirements for 
the degree of Masters in Medicine (Internal Medicine) 
 
 
Johannesburg 2017 
 
 
	 II 
TABLE OF CONTENTS 
 
DECLARATION………………………………………………… VI 
ETHICAL CONSIDERATIONS .……………………............... VI 
DEDICATION .………………………………………………..... VII 
ACKNOWLEDGEMENTS ……………….………………..….. VII 
PUBLICATIONS AND PRESENTATIONS …………………. VII 
LIST OF ABBREVIATIONS ……………………………....….. VIII 
ABSTRACT …….………………………………………………. X 
  
1. INTRODUCTION  
1.1 Background ……………………….……………………………..…………… 1 
1.2 Renal anatomy and classification ……………………………..…………. 2 
1.3 Primary glomerular disease ……………………………………….……… 3 
1.3.1 Proliferative Glomerulonephritis …………………………….………… 4 
1.3.1.1 IgA nephropathy/ Mesangioproliferative Glomerulonephritis…... 4 
1.3.1.2 Membranoproliferative/ Mesangiocapillary Glomerulonephritis.. 6 
1.3.2 Non-proliferative Glomerulonephritis ………………………...……..... 7 
1.3.2.1 Minimal Change Disease ……………………………………………… 7 
1.3.2.2 Focal Segmental Glomerulosclerosis……………………………….. 8 
1.3.2.3 Membranous Glomerulonephritis …………………………………… 11 
1.4 Epidemiology …………………………………………………………...……. 12 
1.4.1 South African Experience …………………...…………………...…… 12 
	 III 
1.4.2 African Experience ………………………………………..……………… 13 
1.4.3 International Experience ……………..………………………...……….. 14 
1.5 Biopsy practices ………………………………..…………………………… 15 
      
2. METHODS AND RATIONALE  
2.1 Aim ……………………………………………………………………………... 19 
2.2 Study objectives …………………………………………………………….. 19 
2.3 Study description ……………………………………………..…….….…… 20 
2.4 Study population ………………………………………..………….…….…. 20 
2.5 Inclusion criteria …………………………………………………...…….….. 20 
2.6 Exclusion criteria ……………..………………………..………………..….. 21 
2.7 Site of study ……………………………………………………………....….. 21 
2.8 Method …...……………………………………………………….………..…. 21 
2.9 Definitions ………………………………………………………….……….... 23 
2.10 Variables ……………………………………………………………..……… 25 
2.11 Data Analysis ………………………………………………….………….... 26 
  
3. RESULTS  
3.1 Overview of records ……………………………………………..…………. 27 
3.2 Glomerular disease by indication to biopsy ……………………….….. 30 
3.3 Primary glomerular disease and gender ……………………….………. 36 
3.4 Primary glomerular disease and ethnicity …………………….……….. 36 
3.5 Primary glomerular disease and age group …………………….……... 39 
3.6 Primary glomerular disease and creatinine/ eGFR………………..…... 42 
3.7 Primary glomerular disease and albumin ………………………….…... 43 
	 IV 
3.8 Primary glomerular disease and haemoglobin ………………….…….. 44 
3.9 Primary glomerular disease and dyslipidaemia ………………….….... 45 
3.10 Primary glomerular disease and urine white cell count ………….... 46 
3.11 Primary glomerular disease and urine dysmorphic red cells …….. 46 
3.12 Primary glomerular disease and urine casts ……………………….... 48 
3.13 Primary glomerular disease and urine protein: creatinine ratio ….. 50 
3.14 Podocytopathies and biochemical presentation …………………….. 51 
3.15 Primary glomerular disease and blood pressure ……………………. 53 
3.16 Primary glomerular disease patterns over time ……………………... 54 
  
4. DISCUSSION  
4.1 Overview of records ………………………………………………………... 56 
4.2 Glomerular disease by indication to biopsy …………………………… 57 
4.3 Most frequent primary histological pattern ……………………………. 59 
4.4 Primary glomerular disease and gender ……………………………….. 62 
4.5 Primary glomerular disease and ethnicity ……………………………... 63 
4.6 Primary glomerular disease and age group ……………………………. 64 
4.7 Primary glomerular disease and biochemical parameters ………….. 65 
4.8 Primary glomerular disease and urinary parameters ………………… 70 
4.9 Primary glomerular disease and blood pressure ……………………... 72 
4.10 Primary glomerular disease patterns over time ……………………... 73 
  
5. CONCLUSION ……………………………………………………………. 74 
  
  
	 V 
  
6.  STUDY LIMITATIONS AND STRENGTHS  
6.1 Study limitations …………………………………………………………….. 75 
6.2 Study strengths ……………………………………...……………………… 76 
6.3 Future studies ………………………………………………………..……… 76 
  
  
7. REFERENCES ……………………………...……………………………. 77 
  
8. APPENDICES   
A. Data Sheet ………….……………………...………………………………….. 85 
B. Ethics Clearance .………………………...…………………………………... 87 
C. Permission from Clinical HOD ……………………………...……………… 88 
D. Permission from Head Anatomical Pathology ………………………….. 89 
E. Permission from CEO CMJAH ……………………………………………… 90 
 
 
 
 
 
 
 
 
	 VI 
 
DECLARATION 
 
I, Yvette Patchapen, declare that this research report is my own work. It is being 
submitted for the degree of Masters in Medicine in Internal Medicine at the 
University of Witwatersrand, Johannesburg. It has not been previously submitted 
for any degree or examination at this or any other University. 
 
Signed 
 
 
         day of  May  2017 
 
 
 
ETHICAL CONSIDERATIONS 
 
Permission for this retrospective study was obtained from Prof S. Naicker (Head of 
Department, Department of Internal Medicine, Charlotte Maxeke Johannesburg 
Academic Hospital), Dr. T. E. Selebano (Chief Executive Officer, CMJAH), Prof M. 
Hale (Head of Anatomical Pathology CMJAH) and the Ethics Committee of the 
University of the Witwatersrand (Clearance number M122146). See appendix. 
Informed consent was not required as no identifiable patient information was used 
in analysis.   
	 VII 
 
DEDICATED TO  
God,  
my husband Wesley Lazarus,  
my parents and family for their love and support. 
 
ACKNOWLEDGEMENTS 
Dr Malcolm Davies for his academic expertise, supervision and guidance, 
without which this study would not have been possible. 
All the renal patients whose biopsy reports were used in this study. 
Prof Sarala Naicker and Prof Graham Paget - Heads of Division of 
Nephrology. 
My husband and parents for their continued support. 
Mitan Nana for his technical expertise and time. 
 
PUBLICATIONS AND PRESENTATIONS 
Poster presentation to the South African Renal Congress, Cape Town 9-11 
September 2016. Abstract to be published in African Journal of Nephrology. 
 
 
 
 
 
	 VIII 
LIST OF ABBREVIATIONS 
 
• AKI Acute Kidney Disease 
• Anti GBM Anti Glomerular Basement Membrane 
• ANA                     Anti Nuclear Antibodies 
• ANCA                  Anti neutrophil cytoplasmic antibodies 
• ANOVA               Analysis of variance 
• APOL 1                Apolipoprotein L1 gene 
• ATIN                   Acute Tubulointerstitial nephritis 
• ATN                    Acute Tubular Necrosis 
• BFH                    Benign Familial Haematuria 
• CHBAH               Chris Hani Baragwanath Academic Hospital 
• CMJAH               Charlotte Maxeke Johannesburg Academic Hospital 
• CKD                    Chronic Kidney Disease 
• DDD                    Dense Deposit Disease 
• DPGN                  Diffuse Proliferative Glomerulonephritis 
• EM                       Electron Microscopy 
• eGFR                   Estimated Glomerular Filtration Rate 
• ESRD                   End Stage Renal Disease 
• FSGS                   Focal Segmental Glomerulosclerosis 
• GGS  Global Glomerulosclerosis   
• GN  Glomerulonephritis 
• Hb                         Haemoglobin 
• HT                         Hypertension 
• IgA                         Immunoglobulin A 
	 IX 
• IMF  Immunofluorescence 
• JHB                     Johannesburg 
• KDIGO                Kidney Disease Improving Global Outcome 
• MCD                    Minimal Change Disease 
• MesPGN              Mesangioproliferative glomerulonephritis 
• MGN Membranous Glomerulonephritis 
• MPGN              Membranoproliferative Glomerulonephritis 
• MYHC 9 Myosin Heavy Chain 9 
• NS                     Nephrotic Syndrome 
• NV                       Necrotising Vasculopathy 
• NHLS                   National Health Laboratory Services 
• NSAIDS               Non-Steroidal Anti Inflammatory Drugs 
• PCR                     Protein: Creatinine Ratio 
• PLA2R1               M Type Phospholipase A2 Receptor 
• PRB                     Percutaneous Renal Biopsy 
• SADTR                South African Dialysis and Transplant Registry 
• SD                       Standard Deviation 
• SLE                     Systemic Lupus Erythematosus 
• SuPAR                 Soluble Plasminogen Activating Receptor 
• Thin GBM Thin Glomerular Basement Membrane 
• TNF                    Tumour Necrosis factor 
• TRAIL              TNF related apoptosis inducing ligand 
• USRDS              United States Renal Data System 
 
 
 
	 X 
ABSTRACT 
Background   
Glomerular disease is a frequent and important cause of renal dysfunction. Current data on 
the patterns of glomerular disease in South Africa is lacking. The aim of this study was to 
characterize the prevalence and nature of presentation of primary glomerular disease at 
Charlotte Maxeke Johannesburg Academic Hospital. 
Materials And Methods   
This single center, retrospective observational study was performed on adult native renal 
biopsies over a 10 year period from 2001 - 2010. A total of 1495 native renal biopsies were 
reviewed. After exclusion of common secondary causes, the results of 194 patients with 
primary glomerular disease were evaluated. 
Results   
The most frequent primary glomerular disease was FSGS (29.8%) followed by MN (19.5%), 
MPGN (18%), MCD (17%) and IgAN (3%). Nephrotic range proteinuria (60.5%) and 
unexplained renal dysfunction (24.2%) were the most common indications for biopsy. There 
was a 59.4% male predominance. From the 73.9 % of patients of African descent, 34.1% 
presented with FSGS.  The majority of patients (62.9%) were aged between 18-49 years with 
30.3% of them presenting with FSGS. FSGS presented with a median creatinine 183.5 [101 - 
476] mmol/l and mean UPCR (0.89 ± 0.66) g/mmol. There were no statistically significant 
differences in albumin, haemoglobin and triglycerides between the glomerular disease 
subtypes. The highest urine leucocytes and dysmorphic red cells were from the IgAN subtype. 
Most patients, 56.8% had no casts observed, and 39.1% were hypertensive. No change in the 
pattern of glomerular injury was observed over the course of the study. 
Conclusion 
Glomerular pathology is more common in younger patients. FSGS is more common than other 
glomerular pathologies in our setting; which may partly be due to local biopsy practices and 
patient demographics. Clinical parameters do not adequately predict biopsy findings.
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1. INTRODUCTION 
1.1 Background 
Current renal histological data demonstrates temporal and regional variation in the 
patterns of primary glomerulonephritis (GN)1. Whilst some of this variation may be 
explained by differences in locally accepted indications for biopsy, there appears 
to be a role for certain patient-related factors (such as age, sex, and race) in 
determining the patterns of glomerular disease.  
 
True geographic variation in the pattern of glomerular disease may exist between 
the various populations of the world, due to differences in the native environment, 
socioeconomic status, and prevalence of certain infections2. Such geographic 
variation may partially be explained by the hygiene hypothesis in which a 
persistence of the Th2 response is proposed to explain the marked increase in 
allergies that has been observed in industrialized societies. Certain types of 
glomerular pathology are postulated to be caused by an overzealous Th2 immune 
response, (membranous nephropathy MN, minimal change disease MCD, and 
immunoglobulin A nephropathy IgAN). The higher prevalence of IgAN and MCD in 
industrialized countries would thus be in keeping with the hygiene hypothesis2. 
 
From available data it appears that glomerular disease is more prevalent in 
developing countries such as South Africa where patients have a poorer response 
to therapy and a greater rate of progression to end stage renal disease (ESRD). 
This is of particular concern because of the limited availability of renal replacement 
therapies in the developing world3.  
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1.2 Renal anatomy and classification   
 
A nephron is comprised of a renal tubule and its glomerulus. Each kidney has 
approximately 1.3 million nephrons. The glomerulus is formed by the invagination 
of capillaries into the dilated, blind end of the nephron known as the Bowmans 
capsule. The glomerulus is supplied by an afferent arteriole and drained by an 
efferent arteriole. The capillary endothelium and the podocytes separate 
glomerular filtrate from blood4. The stability of the glomerulus depends on the 
integrity of the basement membrane, mesangial cells and podocytes. Disruption of 
this structure leads to predictable architectural lesions5. 
 
Renal dysfunction may be classified as acute kidney injury (AKI) or chronic kidney 
disease (CKD). Irrespective of the underlying pathology, once a considerable 
portion of renal tissue has been destroyed, a continued deterioration in the 
glomerular filtration rate over time is related to a loss of viable nephrons5.  
 
Various aetiologies may be implicated in the progression of renal dysfunction 
including: 
• pre-renal causes such as hypovolaemia, cardio renal, hepato-renal syndromes 
and non-steroidal anti-inflammatory drugs (NSAIDS) 
• intrinsic renal vascular causes which include nephrosclerosis secondary to 
hypertension and microangiopathic haemolytic anaemia 
	 3 
• intrinsic glomerular disease which may be subcategorized as primary 
(idiopathic, not associated with systemic disease) or secondary (such as 
paraneoplastic, drug induced, systemic auto immune disorder) 
• intrinsic tubular and interstitial causes, including: 
o acute - acute tubular necrosis (ATN), acute interstitial necrosis (AIN), cast 
nephropathy 
o chronic - polycystic kidney disease (PCKD), nephrocalcinosis, sarcoidosis 
• obstructive nephropathy such as prostatic disease and renal calculi6 
 
1.3 Primary glomerular disease 
 
Glomerular diseases have a variety of clinical presentations including: 
• Asymptomatic 
• Hypertension 
• Oedema 
• Haematuria 
• Proteinuria (normal excretion is < 150mg/24hrs) 
• Urinary abnormalities such as casts, dysmorphic red cells and leucocyturia 
• Acute kidney injury7 
 
Proteinuria is the hallmark of glomerular disease8. Glomerular disease may be 
classified as either primary or secondary. Primary disease may be idiopathic or 
restricted to the kidneys, whilst secondary is usually associated with more 
systemic or generalized disease9. 
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Irrespective of the initial insult, inflammatory pathways are activated leading to 
complement activation, coagulation cascades and overproduction of pro-
inflammatory cytokines. This leads to chemotaxis, cell lysis, fibrin deposition and 
apoptotic failure. Cytokine release results in cellular proliferation of parietal cells 
and acute glomerular crescent formation. Overproduction of proteases and 
antioxidants lead to fibrosis stimulated by platelet derived growth factor (PDGF) 
and transforming growth factor beta (TGF β). After prolonged injury, 
haemodynamic alteration leads to hyperfiltration and intraglomerular hypertension 
with sclerosis. Thus, the initial inflammatory process may progress to fibrosis and 
irreversible scarring9. 
 
1.3.1 Proliferative glomerulonephritis 
1.3.1.1 IgA nephropathy / Mesangioproliferative glomerulonephritis 
 
IgA nephropathy (IgAN) was first recognized in 1968 by Jean Berger and is 
therefore also known as Berger’s disease10. IgAN is the commonest of all 
glomerulonephritides in the United States of America (USA)11. Micro or 
macroscopic haematuria is the usual presentation but no clinical pattern is 
pathognomonic. Peak incidence is between the second and third decades with a 
female: male ratio of 1:2. The gross histological pattern associated with IgAN is 
classically that of mesangioproliferative GN with cellular proliferation 
predominantly affecting the mesangium and paramesangial deposition of IgA 
together with alternative pathway complement components9. 
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IgAN is unique amongst the glomerulonephritides as it is identified by the presence 
of an immune reactant instead of any morphological finding on renal biopsy. An 
infectious source has long been suspected however no organism has been 
consistently implicated10. 
 
IgA is the most common immunoglobulin in the body and is primarily associated 
with mucosal defense. Two subclasses of IgA are produced, namely IgA1 and 
IgA2 10. Overproduction of systemic IgA1 polymers by plasma cells is associated 
with deposition in the kidney. Abnormal glycosylation of IgA may facilitate this 
deposition by promoting self-aggregation forming immune complexes with 
mesangial affinity. Serum IgA levels are raised in 50% of patients with normal 
serum complement, as complement activation is confined to the kidneys9. Studies 
of renal biopsies support a role for PDGF and TGF β. These features are not 
exclusive to IgAN and are likely involved in all forms of mesangioproliferative GN10.  
 
The hallmark on immunofluorescence is diffuse mesangial polymeric IgA with C3 
being deposited in about 90% of cases. Electron microscopy shows dense 
deposits restricted to mesangial and paramesangial areas10. 
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1.3.1.2 Membranoproliferative glomerulonephritis (MPGN) / 
Mesangiocapillary glomerulonephritis 
 
MPGN types 1 and 2 are the commonest subtypes of this infrequent form of 
glomerular disease. Children ranging from 8 - 16years old are usually affected12. 
Clinical presentation includes microhaematuria and sub-nephrotic range 
proteinuria (35%), nephrotic syndrome with mild renal dysfunction (35%), 
chronically progressive GN (20%), or nephritic syndrome with rapidly declining 
renal function with proteinuria and red blood cell casts (10%). Hypertension is 
present in 50 - 80% of patients13. 
Type 1 
Features on light microscopy include diffuse capillary wall thickening, increased 
mesangial matrix and endocapillary hypercellularity with a hypersegmented or 
lobular appearance to the glomerulus12. Immunofluorescence staining reveals 
peripheral granular or band-like staining for complement factor C3 and 
immunoglobulin. The ultra structural hallmark on electron microscopy is mesangial 
interposition in an expanded sub endothelial region containing electron dense 
immune deposits12. 
The pathophysiology highlights the immune complex-mediated nature of type 1, 
however the identity of the nephrogenic antigen is still unknown. Sources of 
antigen may include infections, neoplasms, hereditary diseases and autoimmune 
diseases12. Type I MPGN has similar findings to lupus nephritis (LN). Activation of 
the classical complement pathway with decreased serum C4 levels is found in 
idiopathic type 1 MPGN9. 
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Type II 
Type II MPGN is known as dense deposit disease (DDD) as the classical finding is 
that of dense material deposited within the membranes of glomeruli, Bowmans 
capsule and tubules12. Activation of the alternative complement pathway results in 
decreased serum C3 levels associated with C3 nephritic factor (an antibody 
leading to unregulated initiation of the complement cascade). The pathogenesis is 
not well understood but likely implicates intensive cellular proliferation of 
mesangial cells in response to injury. Histologically both type I and II display 
mesangial expansion and thickening of the capillary walls; the distinction between 
them being made on electron microscopy, specifically by the location of 
subendothelial immune deposits12,13. 
 
1.3.2 Non-proliferative glomerulonephritis 
1.3.2.1 Minimal change disease (MCD) 
 
MCD is implicated in the aetiology of nephrotic syndrome in about 90% of children 
under 10years. A cardinal clinical feature is the fairly acute onset of proteinuria / 
nephrotic syndrome. Haematuria and hypertension are unusual12. It is 
characterised by an absence of gross histological glomerular abnormalities; 
however, electron microscopy shows evidence of fusion and effacement of 
epithelial cell foot process. The degree of effacement appears to relate more with 
the timeline of active nephrotic syndrome rather than the level of proteinuria. The 
most common feature on immunofluorescence is low-level mesangial staining of 
IgM14.  
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The pathogenesis is unclear but is probably a consequence of dysregulation of a T 
cell subset. This is supported by the knowledge that a glomerular permeability 
factor is created by human T cell hybridomas. Lymphocytes have sub optimal 
reactivity when confronted with mitogens. T cells produce a lymphokine that 
increases glomerular permeability protein15. Haemopexin is a protein normally 
present, but an active isoform increases glomerular permeability due to enhanced 
protease activity. Interferon α, β and interleukin 12 are important inducers of T 
helper cell development, immunity, inflammation and delayed hypersensitivity. 
Patients with MCD frequently display a delayed type hypersensitivity response15.  
 
The immune system is complex and dysregulation seems to be more diverse than 
just T cells16. Further research is required in this area. There have, for example, 
been suggestions of a modification in tumor necrosis factor (TNF) related 
apoptosis inducing ligand (TRAIL) in peripheral serum mononuclear cells. Genetic 
factors include heterozygous amino acid changes in nephrin and podocin12. 
 
1.3.2.2 Focal segmental glomerulosclerosis (FSGS) 
FSGS is a histological pattern of glomerular injury that may be primary (idiopathic) 
or secondary to various aetiologies including genetic mutations, circulating 
permeability factors, viral infections, drug toxicities and haemodynamic stress17. 
The aetiology of idiopathic FSGS is unknown; however, genetic mutations 
regulating the cytoskeletal framework of the podocyte are likely to be responsible 
for many such cases that remain “idiopathic” due to lack of genetic testing17. 
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Five different gross histological patterns have been identified: 
• Perihilar variant 
• Cellular variant 
• Tip variant 
• Collapsing variant  
• Not otherwise specified18 
Podocyte injury is a central pathogenic mediator leading to altered cell signaling, 
reorganization of actin skeleton and resultant foot process effacement.  FSGS is 
thus considered a podocytopathy. Podocyte injury is multifactorial and may occur 
in response to reduction in support factors like nephrin signaling, or increase in 
angiotensin II or mechanical strain. Angiogenic factors like TGF α, PDGF and 
vascular endothelial growth factor (VEGF) recruit monocytes, macrophages and T 
cells that release additional cytokines like IL 1 and TNF α. This inflammation, 
coupled with mechanical stress and plasma proteins directly injures the 
tubulointerstitium and leads to glomerular collapse. Cell to cell spread of podocyte 
injury explains the characteristic segmental nature of the sclerosing lesion17,19. 
Myosin heavy chain 9 (MYHC 9) encodes for the heavy chain of non-muscle 
myosin IIA that is a component of the podocyte cytoskeleton involved in 
contractility. MHYC 9 is ubiquitous in glomeruli and podocytes and loss of this 
gene leads to glomerular injury and kidney disease20. 
African Americans have long been known to have a greater risk of idiopathic 
FSGS when compared to their Caucasian counterparts. Recent studies have 
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identified an association between the apolipoprotein 1 (APOL 1) gene (specifically 
the risk-associated allele variants G1 and G2) on chromosome 22q13 and primary 
FSGS, HIV-associated nephropathy and hypertensive nephropathy (all of which 
histologically share an FSGS morphology) in these patients21. 
Both MYHC 9 and APOL 1 are genetic factors that are recognized as prominent 
risk factors for FSGS in patients of African descent17.  Risk variants in MYHC 9 
and APOL 1 are in strong linkage disequilibrium; the two APOL 1 risk alleles are 
common in African chromosomes but absent from European chromosomes12. 
Genetic variation at the MYHC 9 locus assists in explaining the burden of FSGS 
and hypertensive end stage renal disease amongst African Americans12.  
The APOL 1 gene however has a stronger association with non-diabetic chronic 
kidney disease than MYHC 9. APOL 1 is involved in lysis of Trypanosoma brucei 
rhodensiense, a known culprit for sleeping sickness, which is common in Africa. 
This APOL 1 gene has likely evolved under selective pressure to convey a survival 
advantage to offspring carrying the mutation by early red cell lysis preventing 
maturation of the red cell 22. 
Clinical presentation includes varying degrees of proteinuria, nephrotic syndrome, 
haematuria, hypertension and renal dysfunction17. 
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1.3.2.3 Membranous glomerulonephritis (MN) 
 
MN is one of the most frequent causes of nephrotic syndrome in adults aged 40-50 
years. Primary/ idiopathic disease accounts for the majority of cases. Secondary 
causes include autoimmune diseases, infections, malignancy and drugs12. Primary 
MN is an immune complex glomerular disease with IgG and complement deposits 
developing predominantly beneath podocytes. The podocyte injury results in 
increased glomerular permeability leading to varying degrees of proteinuria23.  
 
Light microscopy shows thickening of the glomerular capillary wall. 
Immunofluorescence and electron microscopy reveal diffuse finely granulated 
immune deposits and electron dense deposits respectively in the sub epithelial 
space that are regarded as pathognomonic23. 
 
Antibodies directed to M type phospholipase A2 receptor (PLA2R) on podocytes is 
the favored hypothesis for primary MN. These antibodies are predominantly IgG4. 
AntiPLA2R antibodies are found in serum of 70-75% of all patients with primary 
disease but are rarely seen in secondary forms12. 
 
Nephrotic syndrome occurs in 70-80% of patients at clinical presentation with the 
remainder presenting as subnephrotic or asymptomatic proteinuria. Although 
microscopic haematuria is common (30-40%), red cell casts are rare. Serum 
complement levels and renal function are usually normal at presentation23. 
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1.4 Epidemiology 
1.4.1 South African experience 
 
Available literature pertaining to the pattern of renal disease in South Africa (SA) 
suggests that glomerular disease is more frequent in patients of black African 
descent. This may reflect a background milieu of chronic parasitic, bacterial and 
viral infections produced by socio-economic and geographical factors 
superimposed on a genetic susceptibility24,25. 
 
The South African Dialysis and Transplant Registry in 1994 reported the causes of 
ESRD to be secondary to glomerulonephritis in 52.1% of patients25. 
In a study carried out at Chris Hani Baragwanath Hospital (CHBAH) between 
October 1972 and December 1976 chronic GN was found to be the cause of 
biopsy confirmed ESRD in 40 % of cases26. 
 
In Bloemfontein between 1997- 2006, 1216 biopsies were reviewed. Nephrotic 
syndrome was the most common indication for renal biopsy, with the histology 
showing FSGS to be most common primary glomerular disease followed by 
MPGN, MN and MCD. IgAN was the most infrequent finding27. 
 
A retrospective study of 1284 native biopsies from Cape Town between January 
2000 to December 2009 found mesangiocapillary GN 20.4% to be the most 
frequent histological finding followed by mesangioproliferative 19.2%, MN 18.5%, 
crescentic and necrotizing GN 11.4%, FSGS 10.5%, post-infectious GN 8.2%, 
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MCD 6.0% and lastly IgAN 5.8% 28. Notably, that sample population (53.7% 
coloured, 42.2% black and 3.9% white) was different to this study. 
 
Available data on the patterns of glomerular disease in South Africa and the 
Gauteng province in particular is nevertheless scanty, and where available, 
outdated. The aim of this study is to improve available data regarding the 
prevalence and nature of glomerular disease in this area. 
  
1.4.2 African experience 
Accurate and comprehensive statistics regarding the pattern of glomerular disease 
is lacking in Africa. This represents an important area of research since glomerular 
disease is believed to be both more prevalent and more severe in Africa than in 
Western countries25,29. 
 
Available data suggests that 2 to 3% of medical admissions may be attributed to 
renal related complaints, with a large proportion being due to glomerular disease, 
which is often characterized by poor response to treatment and progression to 
CKD25. Although there is lack of registry data in sub-Saharan Africa, CKD seems 
to be 3-4 times more frequent in developing countries than in the developed 
world30. 
 
A cross sectional study in Sudan in 2010 - 2011 reviewed 83 adult patients. The 
findings revealed a diagnosis of primary GN in 71 patients (85.5%) with the major 
indication for biopsy being nephrotic syndrome 46.5% followed by unexplained 
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elevations in renal parameters 33.8%. FSGS was the most common biopsy finding 
in 29.6%, followed by MPGN 26.8%, MCD 16.9% and least common IgAN 5.6% 31.  
Primary GN remains a leading cause of end-stage renal disease (ESRD) in many 
developing countries and is likely under reported with many patients being 
undiagnosed due to late presentation or unavailable diagnostics. 
 
1.4.3 International experience  
 
The most significant contributors to ESRD in the USA as reported by the United 
States Renal Data System (USRDS) are diabetes 37%, hypertension 25% and GN 
14% 32. In European biopsy studies, primary GN is present in up to 49%, with the 
most frequent subtypes being IgAN 38.8%, MN 29.4%, MCD 9.8%, MPGN type 1 
9.6% and FSGS 5.7% 1.  
 
In the USA, analysis of data suggests that IgAN is the most frequently found 
primary glomerular pathology and the most frequent cause of ESRD amongst 
young adult Caucasians, whilst FSGS is more common in African 
Americans11,33,34. Such data indicates that different racial groups may have 
different prevalence’s of primary GN. 
 
Data from Europe and the USA such as that reported above is reflective of the 
prevalence of GN within an urbanized and industrialized population. However, as 
previously indicated, socio-economic conditions may play an integral role in 
determining the prevalence and types of primary GN within a population. 
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Brazil has features of both a developed and developing country similar to South 
Africa. Studies from Brazil indicate that primary GN is detected in about half of all 
native renal biopsies. FSGS is the most frequent primary glomerular lesion in this 
population followed by MN and IgAN. Analysis of this study population has also 
shown variation in glomerular disease patterns based on patient age, with FSGS 
being the most frequently detected lesion in children, adolescents, young adults 
and adults; whilst MN predominated in elderly patients33,35. 
 
Patterns of primary glomerular disease were evaluated in an Indian study of 75 
biopsies in 2013, with primary disease detected in 80%. MCD was the most 
common histological pattern followed by IgAN, crescentic GN, FSGS and 
mesangiocapillary GN. Lupus nephritis was the most common aetiology in the 
secondary glomerulonephritis group. This study however also included children, 
which may have resulted in the higher incidence of MCD. The most common 
presentations were oedema 62.7%, haematuria 46.7%, nephrotic syndrome and 
renal impairment 30.7% each36. 
 
1.5 Biopsy Practices  
 
Prior to the advent of renal biopsy, insight into clinicopathological correlation was 
suboptimal. Iversen and Brun performed percutaneous native renal biopsy in 1951 
using an aspiration needle technique, which yielded an adequate sample in about 
53%. Drs. Robert Kark and Robert Muehrcke improved on this technique using a 
Franklin-modified Vim-Silverman needle (a precursor to the current needle) that 
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collected tissue and sheared it off. In 1954, they reported a success rate of 96% 
with no major complications37. 
 
Modifications and updates in imaging and biopsy needles have resulted in 
acquiring optimal renal tissue in 95% of biopsies37. Current practice at CMJAH 
involves use of the spring-loaded tru-cut biopsy needle. 
 
In a systematic review of 34 retrospective and prospective studies, which included 
9474 native kidney biopsies, the approximate incidence of complications using 
real-time ultrasonic guidance was as follows: 
 
#Transient macroscopic hematuria - 3.5 % 
#Requirement for transfusion - 0.9 % 
#Requirement for angiographic intervention to control bleeding - 0.6 % 
#Requirement for nephrectomy to control bleeding - 0.01 % 
#Death - 0.02 %  38 
 
The complication rate resulting in death declined from 0.12% to 0.02% during the 
preceding 50 years, with some studies reporting no deaths39. 
 
Renal biopsy is a vital procedure in the diagnosis, prognosis, and management of 
patients with renal pathology. This procedure has proven invaluable not only by 
the ability to obtain tissue but also by the safety profile40. 
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For interpretation of biopsy an adequate sample consisting of two cylinders of 
tissue of minimum length 1cm and diameter of 1.2mm is required; there should be 
adequate cortical tissue in the samples – for glomerular lesions a minimum of 5 
glomeruli are needed, and for tubular interstitial lesions a minimum of 6 – 10 are 
required41. 
 
Contraindications to renal biopsy may be sub classified as absolute or relative: 
 
1. Absolute 
• Small kidney size 
• Coagulopathy 
• Uncontrolled hypertension ( >160/95 mmHg) 
 
2. Relative 
• Solitary kidney 
• Uncooperative patient 
• Patient who is unable to lie supine41 
 
Renal biopsy may be considered as a diagnostic procedure in the following clinical 
situations: 
• nephrotic syndrome (NS) 
• prolonged non-resolving acute renal failure   
• rapidly progressive renal failure  
• systemic diseases with co-existent renal dysfunction 
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• non-nephrotic range proteinuria 
• isolated microscopic hematuria 
• unexplained chronic renal failure 
• renal transplant dysfunction 
• patients with a history of familial renal disease42 
 
The most common indications for biopsy in a retrospective review at a tertiary 
hospital in South India over 19 years between 1990 and 2008 were nephrotic 
syndrome 49%, chronic renal failure 13.6% and rapidly progressive renal failure 
12% 43. 
 
Indications for biopsy in Sudan in 2011 were reported as nephrotic syndrome 
46.5%, unexplained renal impairment 33.8%, asymptomatic microscopic 
hematuria with minimal non-nephrotic range proteinuria 8.5%, nephritic syndrome 
7%, and isolated non-nephrotic range proteinuria 4.2% 31.  
 
In Johannesburg at Chris Hani Baragwanath Hospital, a study evaluating biopsy 
practices for the period 1982 - 2011, reported the most common indications for 
biopsy to be nephrotic syndrome 47.1%, acute kidney injury 19.8%, asymptomatic 
urinary abnormalities 8.1% and nephrotic / nephritic syndrome 6.2% 44. 
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2. METHODS AND RATIONALE 
 
2.1 Aim 
 
There is currently a lack of data regarding the prevalence of primary glomerular 
disease in the South African context.  The aim of this study was therefore to 
characterize the prevalence and nature of presentation of glomerular disease in 
the patients undergoing native kidney biopsy at Charlotte Maxeke Johannesburg 
Academic Hospital. 
 
2.2 Study objectives 
 
2.2.1 Primary objective 
1. To determine the overall prevalence of primary glomerular disease in the 
population of patients undergoing native kidney biopsy at Charlotte Maxeke 
Johannesburg Academic Hospital. 
 
2.2.2 Secondary objectives 
1. To characterize the types of primary glomerular disease in the context of the   
locally practised indications for native kidney biopsy. 
2. To determine the association of patient factors such as age, sex, and race on 
the prevalence and relative frequencies of primary glomerular disease in this 
patient population. 
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3. To characterize the clinical presentation of glomerular disease within this 
population and evaluate the differences (if any) in clinical presentation in the 
various types of primary glomerular diseases. 
 
2.3 Study description  
This is a single center retrospective observational study conducted on all patients 
who underwent native kidney biopsies at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) during the period 2001-2010.  The study contains 
descriptive and comparative elements. 
 
2.4  Study population 
All native renal biopsies undertaken on patients aged 18 years and older between 
the years 2001 and 2010 were considered for inclusion in this study. 
 
2.5 Inclusion criteria 
 
All patients who underwent kidney biopsy during the period 1/1/2001 – 31/12/2010 
at CMJAH were included in this study if the following criteria were met: 
1.  Native renal biopsy was performed. 
2. Biochemical, serological and histopathological evaluation indicated the 
presence of primary glomerular disease.  
3. All patients with renal histopathological evidence of primary glomerular disease 
and sufficient biochemistry for analysis. 
4. Patients were 18 years or older. 
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2.6 Exclusion criteria 
Patients were excluded from this study if the following criterion were met: 
1. Retrospective review of clinical and / or histopathological data indicated the 
possibility of a secondary cause for the glomerular lesion diagnosed. 
Secondary glomerular diseases excluded from analysis after clinical review    
and biochemical / histological parameters included: 
• Lupus nephritis 
• Diabetic nephropathy 
• Hypertensive nephropathy 
• HIV associated nephropathy 
 
2.7 Site of study  
This study was undertaken in the Division of Nephrology, Department of Internal 
Medicine, CMJAH, South Africa. CMJAH is a quaternary level hospital that serves 
as a referral hospital in Johannesburg. The patient population resident in these 
areas is heterogeneous and includes patients of African, Indian, Caucasian and 
Coloured (mixed race) ancestry. 
 
2.8 Method 
Records from all patients diagnosed with primary glomerular disease on native 
kidney biopsy at CMJAH between 1/1/2001 – 31/12/2010 and meeting the 
inclusion criteria were analyzed. 
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1. The prevalence of primary glomerular disease overall was determined as a 
percentage of all native kidney biopsies performed regardless of indication for 
biopsy 
 
1.1 The prevalence of the various forms of primary glomerular disease, for 
example, FSGS, MN, MPGN, MCD, IgAN was determined as a percentage of 
the total number of diagnoses of primary glomerular disease as a whole. 
 
1.2 Since patterns of glomerular disease may be affected by local biopsy 
practices, the prevalence of the various forms of primary glomerular disease 
was further characterized in the context of the indication for biopsy. For 
example, the prevalence of primary FSGS, MN, MPGN, and MCN were 
determined within the subgroup of patients undergoing native kidney biopsy for 
investigation of the nephrotic syndrome, as well as for those undergoing 
biopsy for evaluation of unexplained proteinuria, or urinary abnormalities, or 
renal dysfunction. 
 
2. The effect of patient factors on the prevalence of primary glomerular disease 
was determined by evaluation of the relative frequencies of each of the 
subtypes of primary glomerular disease encountered within the patient 
subgroups of sex, race, and age. 
 
3. The indication for renal biopsy was analyzed in respect of the following 6 main 
categories: 
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• Nephrotic range proteinuria 
• Sub nephrotic range proteinuria 
• Nephrotic /nephritic features 
• Nephritic features 
• Unexplained renal dysfunction 
• Abnormal urine sediment                 (See definitions in 2.9 below) 
 
Many patients had more than one indication for biopsy but the most prominent 
indication was used in this study. This was ascertained by reviewing the notes 
from the renal biopsy summary; in cases where this was not clear, the laboratory 
findings closest to the renal biopsy date that showed the greatest derangement 
from normal were used as indicators. 
 
2.9 Definitions 
As per the 2012 KDIGO Clinical Practice Guidelines on Glomerulonephritis, the 
following definitions were applied:	
• Nephrotic range proteinuria was defined as a spot uPCR  > 0.3-0.35 g/mmol 
• Sub-nephrotic proteinuria was defined as a spot uPCR > 0.03g/mmol but < 
0.3g/mmol 
• Nephrotic syndrome was defined by the presence of: 
o proteinuria  > 3.5g/day or spot UPCR  >  0.3g/mmol 
o hypoalbuminaemia  < 30g/l 
o oedema 
o dyslipidaemia45 
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• Nephritic syndrome was defined by the presence of:  
o microhaematuria 
o hypertension  
o proteinuria usually non nephrotic range,  
o abnormal renal function45 
 
• Microhaematuria was defined by the presence of more than two red blood 
cells (RBCs) per high-power field in a spun urine sediment or more than 10 
× 10 6 RBCs/l 7. 
 
• Unexplained renal dysfunction – acute or chronic 
o Acute kidney injury - A rise in the serum creatinine concentration that 
has developed within hours to days. The criteria includes an increase 
in serum creatinine by 27 micromol/L or ≥1.5 times the baseline 
value within 48 hours (Acute Kidney Injury Network [AKIN] criteria), 
or an increase ≥1.5 times the baseline value within seven days 
(RIFLE criteria and Kidney Disease: Improving Global Outcomes 
[KDIGO]-AKI)  
o Chronic kidney disease - The National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF-K/DOQI) and the KDIGO 
CKD guidelines define CKD as being present if glomerular filtration 
rate (GFR) has been recorded as being persistently below 60 
mL/min/1.73 m2 or if abnormalities of urinalysis or histology or renal 
imaging have been present for three months or more. 
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• Estimated GFR was determined using the Modification of Diet in Renal 
Disease (MDRD) Study Group formula. 
eGFR =  32788 × standardized creatinine  −1.154 × age−0.203 × 1.212 [if black] 
× 0.742 [if female], where GFR is expressed as mL/min/1.73 m2 of body 
surface area, and creatinine is expressed in μmol/L 46. 
 
• Abnormal urine sediment 
o Proteinuria and haematuria as above 
o Leucocyturia 
o Dysmorphic red cells 
o Casts: granular, hyaline, waxy, red cell, cellular and combination 
 
2.10 Variables 
The clinical presentation of the various forms of primary glomerular disease was 
evaluated in the context of the following parameters: 
2.10.1 serum creatinine  
2.10.2 serum albumin 
2.10.3 serum total cholesterol and triglyceride concentration 
2.10.4 haemoglobin 
2.10.5 urine white cell count 
2.10.6 urine dysmorphic red cells 
2.10.7 urine casts 
2.10.8 urine protein: creatinine ratio 
2.10.9 non-invasive arterial blood pressure 
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2.11 Data analysis 
All continuous variables were tested for normality of distribution by visual 
inspection of frequency plot and the Shapiro-Wilk W test. The mean and standard 
deviations were used as the central and dispersal measurements for normally 
distributed data and the median and interquartile range were used for non-
parametric data. Frequencies and percentages were used to describe categorical 
data. Differences in the various forms of primary glomerular disease with regards 
to demographics (patient age, sex, and race) and clinical presentation were 
analyzed using the ANOVA (parametric data), Friedman (non-parametric) tests; a 
Chi squared test was used for categorical variables. 
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3. RESULTS 
 
3.1 Overview of records 
 
A total of 1495 renal biopsies were performed at Charlotte Maxeke Johannesburg 
Academic Hospital between 1 January 2001 and 31 December 2010. Of these, 
1135 biopsies were excluded from analysis at initial record review for the following 
reasons: 
• Patients under 18 years 
• Transplant kidney biopsies 
• Patients diagnosed with HIV  
• Insufficient records available for analysis of clinical and biochemical data  
The remaining 360 records were subdivided into primary, secondary and non-
glomerular pathology.  
 
Table 3.1.1 Incidence of primary glomerular disease 
Category Count Percentage 
Primary 194 53.8% 
Secondary 145 40.2% 
Non-glomerular 21 5.8% 
Total 360 100% 
 
Table 3.1.2 Secondary causes of glomerular disease 
Category Count Percentage 
Lupus nephritis (LN) 81 55.8% 
Hypertensive (HT) Nephrosclerosis  24 16.5% 
Diabetic Nephropathy 14 9.6% 
Post-infectious Glomerulonephritis 10 6.8% 
Benign Nephrosclerosis 6 4.1% 
Thrombotic microangiopathy (TMA) 5 3.4% 
Primary renal Amyloidosis 2 1.3% 
Multiple Myeloma (MM) 2 1.3% 
Pre-eclampsia /Eclampsia 1 0.6% 
Total 145 100% 
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Figure 3.1.1 Secondary glomerular diseases 
The most common secondary cause for glomerular disease in this study was LN 
(55.8%), followed by HT nephrosclerosis (16.5%), diabetic nephropathy (9.6%), 
post-infectious GN (6.8%), benign nephrosclerosis (4.1%) and TMA (3.4%). The 
incidence of LN far out-weighs HT nephrosclerosis and the other histological sub 
types. Biopsy assists with classification of lupus nephritis which impacts on 
treatment and outcomes. Hypertensive and diabetic nephropathy are relatively 
easily diagnosed on clinical grounds and treatment and outcomes are not as 
varied as is the case with LN and so do not always require biopsy. Thus, local 
biopsy practices may have affected this analysis.   
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Table 3.1.3 Non-Glomerular Reasons for Exclusion 
Category Count Percent 
Acute Tubular Necrosis 11 52.3% 
Chronic Interstitial Nephritis 6 28.5% 
Chronic Pyelonephritis 2 9.5% 
Acute Pyelonephritis 1 4.7% 
Normal Biopsy 1 4.7% 
Total 21 100% 
 
The frequency of primary glomerular disease (53.8%) was higher than that of 
secondary (40.2%) and non-glomerular causes (5.8%). This trend may reflect local 
biopsy practices in our resource-limited setting where patients with known 
underlying aetiologies for the renal abnormalities are not readily biopsied. 
The patterns of primary glomerular disease in the 194 biopsies included in this 
analysis are tabulated in Table 3.1.4. 
 
Table 3.1.4 Subtypes of primary glomerular disease 
Category Count Percent 
Focal Segmental Glomerulosclerosis (FSGS) 58 29.8% 
Membranous Glomerulonephritis (MN) 38 19.5% 
Membrano Proliferative GN (MPGN) 35 18.0% 
Minimal Change Disease (MCD) 33 17.0% 
Global Glomerular Sclerosis of unknown aetiology (GGS) 7 3.6% 
Mesangio-Proliferative GN (MesPGN) 6 3.0% 
IgA Nephropathy (IGAN) 6 3.0% 
Thin GBM Disease (Thin GBM) 3 1.5% 
Diffuse Proliferative GN (DPGN) 1 0.5% 
Immunotactoid Glomerulopathy (Immunotactoid GN) 1 0.5% 
Necrotising Vasculopathy (NV) 1 0.5% 
Anti-GBM Disease (Anti GBM) 1 0.5% 
ANCA Vasculitis (ANCA vasc) 1 0.5% 
Benign Familial Haematuria (BFH) 1 0.5% 
Idiopathic crescentic Glomerulonephritis (Crescentic GN) 1 0.5% 
Dense Deposit Disease (DDD) 1 0.5% 
Total 194 100% 
	 30 
FSGS (29.8%) was found to be the most common cause of primary glomerular 
disease in this study followed by MN (19.5%), MPGN (18%), MCD (17%), GGS 
(3.6%), IgAN (3%) and MesPGN (3%). 
 
3.2 Glomerular disease by indication to biopsy 
 Table 3.2.1 Indication to biopsy 
 
 
 
 
 
 
 
The most common indication for renal biopsy at CMJAH for the period 2001-2010 
amongst patients with primary glomerular, secondary glomerular, and non-
glomerular patterns on renal biopsy (360 records) were nephrotic range proteinuria 
(43.6%) followed by unexplained renal dysfunction (31.9%), nephrotic / nephritic 
features (6.9%), abnormal urinary sediment (3%), sub nephrotic range proteinuria 
(2.7%) and lastly, nephritic features (0.5%). 
 
 
 
 
 
 
 
 
 
Category Count Percentage 
Nephrotic Range Proteinuria 157 43.6% 
Unexplained Renal Dysfunction 115 31.9% 
Lupus Nephritis 40 11.1% 
Nephrotic / Nephritic Features 25 6.9% 
Abnormal Urine Sediment 11 3.1% 
Sub-nephrotic Range Proteinuria 10 2.8% 
Nephritic Features 2 0.6% 
Total 360 100% 
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Figure 3.2.1 Indication for biopsy  
 
Figure 3.2.1 highlights the differences in frequency of the primary, secondary and 
non-glomerular histological patterns diagnosed on biopsy with respect to the 
indication to biopsy. Nephrotic range proteinuria was the indication for biopsy in 
(60.5%) patients with primary glomerular pathology, (24.1%) with secondary 
glomerular pathology and (33.3%) with non-glomerular pathology. Unexplained 
renal dysfunction was the most common indication for biopsy amongst the 
secondary glomerular (38.6%) and non-glomerular (61.9%) histopathology groups. 
These figures may infer a trend for primary glomerular disease to be more frequent 
in the nephrotic range category. There was a difference in the frequency of 
disease category (primary/ secondary and non glomerular) by indication to biopsy 
(p  < 0.001 Pearson Chi Square). 
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Figure 3.2.2 Primary glomerular disease and indication for biopsy 
 
 
 
The most common indication for biopsy across most of the subclasses of primary 
glomerular pathology was nephrotic range proteinuria, except for IgAN and GGS in 
which unexplained renal dysfunction was the most common indication for biopsy 
as illustrated in Figure 3.2.2. 		
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Table 3.2.2 Indication for biopsy amongst the primary glomerular pathologies 
 
Histology 
 
Nephrotic 
Range 
Proteinuria 
 
 
Unexplained 
Renal 
Dysfunction 
 
 
Nephrotic 
Nephritic 
Features 
 
 
Sub 
Nephrotic 
Proteinuria 
 
 
Abnormal 
Urine 
Sediment 
 
 
Nephritic 
 
 
Total 
 
FSGS 
 
38 15 3 0 1 0 57(30%) 
  % 
 
66.6% 26.3% 5.2% 0.0% 1.7% 0.0% 100% 
MN  
 
33 
 
1 2 1 0 
 
0 37(19.4%) 
   % 
 
89.1% 2.7% 5.4% 2.7% 0.0% 0.0% 100% 
MPGN 
 
14 11 7 1 2 0 35(18.4%) 
  % 
 
40.0% 31.4% 20.0% 2.8% 5.7% 0.0% 100% 
MCD 
 
23 4 3 2 1 0 33(17.3%) 
  % 
 
69.7% 12.1% 9.0% 6.0% 3.0% 0.0% 100% 
IgAN 
 
1 4 0 1 0 0 6(3.1%) 
  % 
 
16.6% 66.6% 0.0% 16.6% 0.0% 0.0% 100% 
MesPGN 
 
3 0 1 0 1 0 5(2.6%) 
  % 
 
60.0% 0.0% 20.0% 0.0% 20.0% 0.0% 100% 
NV 
 
0 1 0 0 0 0 1 
Thin 
GBM 
 
1 1 0 0 0 1 3 
Anti-GBM 
 
0 1 0 0 0 0 1 
ANCA 
Vasc 
 
0 1 0 0 0 0 1 
BFH 
 
0 0 0 0 0 1 1 
 DPGN 1 0 0 0 0 0 1 
GGS 
 
1 5 0 1 0 0 7 
Crescentic 
 
0 1 0 0 0 0 1 
DDD 
 
0 1 0 0 0 0 1 
Total 
 
115 46 16 6 5 2 190 
 % 
 
60.5% 24.2% 8.4% 3.1% 2.6% 1.0% 100% 
 
Table 3.2.2 demonstrates the variation in indication for biopsy amongst the most 
frequent types of primary glomerular pathology.  
 
Nephrotic range proteinuria (60.5%) followed by unexplained renal dysfunction 
(24.2%) and nephrotic / nephritic features (8.4%) were the most common 
indications for native renal biopsy in patients with primary glomerular pathologies. 
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Abnormal urinary sediment (2.6%) and nephritic features (1%) were relatively rare 
indications for biopsy in this series.   
Nephrotic range proteinuria was the most common indication for biopsy amongst 
MN (89.1%), FSGS (66.6%), MCD (69.7%), MesPGN (60%) and MPGN (40%). 
Unexplained renal dysfunction was the most common indication for biopsy in IgAN 
(66.6%). Indication for biopsy was significantly associated with the different 
histological subtypes (p  < 0.001 Pearson Chi square). 
 
 
Figure 3.2.3 Podocytopathies and indication for biopsy 
 
 
 	
 		
Nephrotic Range Proteinuria
Unexplained Renal Dy sf unction
Nephrotic / Nephritic Features
Sub-Nephrotic Range Proteinuria
Abnormal Urine Sediment
Indication for Bx
0
5
10
15
20
25
30
35
40
45
Fr
eq
ue
nc
ie
s
 Histology Membranous Glomerulonephritis
 Histology FSGS
 Histology MCD
 Histology Membrano Prolif erativ e GN
	 35 
Table 3.2.3 Podocytopathies and indication to biopsy  
 
Amongst the 57 patients with FSGS, nephrotic range proteinuria and renal 
dysfunction was the indication to biopsy in (66.7% and 26.3%) respectively. 
Among the 37 patients with MN, nephrotic range proteinuria (89.2%) was the most 
common indication for biopsy followed by nephrotic / nephritic features (5.4%).  
Nephrotic range proteinuria (40%), unexplained renal dysfunction (31.4%), and 
nephrotic / nephritic features (20.0%) were the dominant indications to biopsy in 
MPGN.  
Nephrotic range proteinuria (66.7%) was the most common indication for biopsy 
amongst the podocytopathies overall, followed by unexplained renal dysfunction 
(19.1%). Sub-nephrotic range proteinuria and abnormal urine sediment were the 
least documented indications for renal biopsy in this analysis. Most patients with 
FSGS, MCD and MPGN presented with nephrotic range proteinuria and 
unexplained renal dysfunction. The differences in indication to biopsy amongst the 
podocytopathies were significantly different by histological subtype (p = 0.004 
Pearson Chi-square). 
 
Nephrotic 
Range 
Proteinuria 
Unexplained 
Renal 
Dysfunction 
Nephrotic / 
Nephritic 
Features 
Sub-Nephrotic 
Range 
Proteinuria 
Abnormal 
Urine 
Sediment 
Row 
Total 
FSGS 38 15 3 0 1 57 
  % 66.7% 26.3% 5.3% 0.0% 1.8%  
MN 33 1 2 1 0 37 
  % 89.2% 2.7% 5.4% 2.7% 0.0%  
MCD 23 4 3 2 1 33 
  % 69.7% 12.1% 9.1% 6.1% 3.0%  
MPGN 14 11 7 1 2 35 
  % 40.0% 31.4% 20.0% 2.9% 5.7%  
Total 108 31 15 4 4 162 
  % 66.7% 19.1% 9.3% 2.5% 2.5% 100% 
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3.3 Primary glomerular disease and gender 
Table 3.3.1 Observed frequencies of histological subtypes and gender 
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Male 19 32 4 16 24 1 5 6 1 1 0 1 1 1 0 1 113 
Female 18 25 2 16 10 0 2 0 0 0 3 0 0 0 1 0 77 
Total 37 57 6 32 34 1 7 6 1 1 3 1 1 1 1 1 190 
 
The incidence of glomerular disease relative to gender is tabulated in Table 3.3.1. 
There was an overall male preponderance (59.5%) compared to females (40.5%).  
This male dominance was mainly a result of FSGS, MPGN and IgAN; as a similar 
male to female ratio was noted in MN, MCD and MesPGN. There were no 
significant differences in patterns on histological biopsy with respect to gender on 
Pearson Chi square testing p = 0.19 
 
3.4 Primary glomerular disease and ethnicity 
 
Table 3.4.1 Observed frequencies of primary glomerular disease and ethnicity 
Ra
ce
 
M
N 
FS
GS
 
M
es
PG
N 
M
CD
 
M
PG
N 
DP
GN
 
GG
S 
Ig
AN
 
Im
m
un
o 
GN
 
NV
 
Th
in
 G
BM
 
An
ti-
GB
M
 
AN
CA
 V
as
c 
BF
H 
Cr
es
ce
nt
ic
 G
N 
DD
D 
To
ta
l 
Black 27 43 5 27 29 1 5 2 1 0 0 1 1 0 0 0 142 
(73.9%)  
% 19 30
.3 
3.5 19 20.4 0.7 3.5 1.4 0.7 0 0 0.7 0.7 0 0 0 100% 
White 6 8 1 4 2 0 2 3 0 0 3 0 0 1 1 0 31 
(16.1%) 
% 19
.4 
25
.8 
3.2 12.9 6.5 0 6.5 9.7 0 0 9.7 0 0 3.2 3.2 0 100% 
Indian 5 4 0 2 2 0 0 1 0 1 0 0 0 0 0 1 16 
(8.3%) 
% 31
.3 
25
.0 
0 12.5 12.5 0 0 6.3 0 6.3 0 0 0 0 0 6.3 100% 
Total 38 57 6 33 34 1 7 6 1 1 3 1 1 1 1 1 192 
 % 19
.8 
29
.7 
3.1 17.2 17.7 0.5 3.7 3.1 0.5 0.5 1.6 0.5 0.5 0.5 0.5 0.5 100% 
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Table 3.4.1 demonstrates that the majority of all patients biopsied were of black 
ethnicity (73.9%), followed by white (16.1%) and indian (8.3%) patients. Included 
in this series but not tabulated for purposes of simplicity were two coloured 
patients (one diagnosed with FSGS and one with MPGN) and one asian patient 
diagnosed with FSGS.  
 
The percentage of black vs white patients with FSGS, MCD, MPGN MN and 
MesPGN were 30.2% vs. 25.8%, 19% vs 12.9%, 20.4% vs 6.4%, 19.1% vs. 19.5% 
and 3.5% vs. 3.2%, respectively.  
 
In patients presenting with MPGN, 93.5% were black vs 6.5% white, MCD 87% 
black vs 13% white, FSGS 84.3% black vs 15.6% white and MN 81.8% black vs 
18.2% white. In black patients FSGS 30.3% was the most common subtype 
followed by MPGN 20.4% and MCD and MN 19% each.  
 
The study population was predominantly from the black ethnic group and most 
histological subtypes had more patients in the black ethnic group, except for IgAN, 
thin GBM, BFH and Crescentic GN. 
 
Overall, there was no statistical significance in the distribution of histological 
patterns between the ethnic groups (p = 0.242 Pearson Chi-square). 
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Figure 3.4.1 Podocytopathies and ethnicity 
 
 
Figure 3.4.1 illustrates podocytopathy subtype between black and non-black ethnic 
groups. The black to non-black ratios amongst the podocytopathies were MPGN 
(85.3% vs 14.7%), and MCD (81.8% vs 18.2%), FSGS (75.4% vs 24.6%), and MN 
(71% vs 29%). 
 
The distribution of podocytopathy amongst black patients was FSGS (34.1%), 
MPGN (23.0%), MN (21.4%), and MCD (21.4%), compared to non-black patients 
FSGS (38.9%), MN (30.6%), MPGN (17.9%), and MPGN (13.9%). There was no 
statistical significance between the podocytopathy histological subtype and black 
vs non-black patients p = 0.46 Pearson Chi Square. 
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3.5 Primary glomerular disease and age group 
Figure 3.5.1 Primary glomerular disease and age  
 	
Table 3.5.1 Primary glomerular pathology in relation to age group 
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The mean age of all patients was 37.13 years. From Figure 3.5.1 and Table 3.5.1, 
it is noted that the majority of patients were from the 18 - 40 year old age group 
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(62.89%), followed by the 40 - 60 year subgroup (24.74%); and the least number 
of patients from the above 60 year old age group (12.37%).  
 
The most frequent histological subtype in the 18 - 40 age group was FSGS 
(30.3%) followed by MPGN (23%), MCD (19.7%), and MN (12.3%). In the 40 – 60 
year old sub group, MN (27.1%) was the most frequent, closely followed by FSGS 
(25%). Patients in the 60 years and above age group had MN (41.7%) as the most 
frequent glomerular pathology, followed by FSGS (37.5%). The majority of patients 
with MPGN (80%), MCD (72.7%) and FSGS (63.3%) were from the 18 - 40 year 
group. The Pearson Chi Square test indicated a statistically significant difference 
in the frequency of histological patterns of primary glomerular disease and age 
group p = 0.01. This probably reflects the higher numbers of patients in the 18 – 
40 year group. This was not unexpected as primary GN is more common in 
younger patients. 
Figure 3.5.2 Primary podocytopathies and age groups 
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The frequencies of histological pattern of injury per age group are illustrated in the 
line graph Figure 3.5.2. Although all the frequencies were high amongst the 
patients aged 18 – 40, which were highly represented in the sample, it is noted 
that FSGS was most prevalent within the 18 – 40 year age group while MN was 
most prevalent in the 40 – 60 and above 60 year age group. There were no 
patients with MCD above 60 years. 
 
Table 3.5.2 Podocytopathies and age groups 
 
 
Age group  MN FSGS MCD MPGN Row Total 
18 - 40 15 37 24 28 104 
% 14.4 35.6 23.1 26.9 100 
Total % 9.2 22.6 14.6 17.1 63.4 
40 - 60 13 12 9 6 40 
% 32.5 30.0 22.5 15.0 100 
Total % 7.9 7.3 5.5 3.7 24.4 
>60 10 9 0 1 20 
% 50.0 45.0 0 5.0 100 
Total % 6.1 5.5 0 0.6 12.2 
Total 38 58 33 35 164 
 % 23.2% 35.4% 20.1% 21.3% 100% 
 
Among patients aged 18 – 40 years, FSGS (35.6%) was the most common 
histological pattern followed by MPGN (26.9%). MN (34.5%) was the most 
common glomerular pattern among the 40 – 60 years age group followed by FSGS 
(30.0%). MN (50%) followed by FSGS (45%) were the most common histological 
patterns in the 60 years and above age group. On review of the podocytopathies, 
histological subtypes were significantly different amongst the three age groups (p 
= 0.002 Pearson Chi Square). 
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3.6 Primary glomerular disease and creatinine/ eGFR 
Table 3.6.1 Creatinine and histological subtypes 
Histology 
Creatinine 
N Median [Interquartile range ]μmol/l 
Crescentic GN 1                   2154 
NV 1                   1009 
GGS 4 510 [232 - 844.5] 
IgAN 5                   488 [315 - 694] 
Anti-GBM 1                    408 
FSGS 54 183.5 [101 - 476] 
MPGN 34 156.5 [104 - 239] 
MN 32                    92.5 [63 - 140] 
Immunotactoid GN 1                    90 
MCD 29                    79 [65 - 103] 
MesPGN 4                    76 [66 - 177.5] 
Thin GBM 3                    76 [ 75 - 137] 
DPGN 1                    76 
BFH 1                    76 
 
The total mean creatinine was 261.3 ± 352.6 µmol/l. The creatinine value used 
was the one stated on the histology request form or the closest value to the renal 
biopsy date. In histological subtypes with only one patient, no IQR is documented. 
Poor documentation and inadequate records form the majority of the 
undocumented results. Amongst the commoner subtypes, the highest median and 
IQR for creatinine was recorded in patients diagnosed with IgAN 488 [315 - 694] 
μmol/l followed FSGS 183.5 [101 - 476] μmol/l, MPGN 156.5 [104 - 239], MN 92.5 
[63 - 140], MCD 79 [65 - 103] and MesPGN 76 [66 - 177.5] μmol/l). A significant 
difference was noted in the mean creatinine amongst the histological subtypes (p 
< 0.001 Kruskall - Wallis), which suggests that the severity of renal dysfunction at 
presentation is disparate between the histological subtypes. 
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Table 3.6.2 Estimated Glomerular Filtration rate (eGFR) amongst podocytopathies 
Histology N Median [Interquartile Range] mL/min/1.73m2 
FSGS 52 40.9 [12.6 – 86.9] 
MPGN 34 57.4 [30.6 – 77.9] 
MN 30   85.4 [50.6 – 131.5] 
MCD 29     111.7 [79.9 – 137.8] 
 
The median and interquartile range (IQR) for eGFR amongst the podocyopathies 
FSGS, MPGN, MN, MCD were 40.9 [12.6 – 86.9], 57.4 [30.6 – 77.9], 85.4 [50.6 – 
131.5], 111.7 [79.9 – 137.8] mL/min/1.73m2 respectively. The highest median 
eGFR was found in MCD 111.7 mL/min/1.73m2  which is more than twice the value 
for FSGS 40.9 mL/min/1.73m2. . A significant difference in the median EGFR was 
found amongst the podocytopathies (p < 0.001 Kruskall- Wallis), which suggests 
that the severity of renal dysfunction at presentation is disparate between the 
histological subtypes. 
 
 
3.7 Primary glomerular disease and albumin 
Table 3.7.1 Albumin and histological subtypes 
Histology 
Albumin Albumin 
N Mean ± Std.Dev g/L 
IgAN 2 32.5  ± 14.8 
MCD 13             26.2 ± 9.4 
MPGN 9 24.8  ± 7 .2 
MN 16             24.5 ± 9.8 
FSGS 18 24.3  ± 10.3 
Total 67             26.3  ± 9.7 
 
 
A total of 67 values for albumin were found. The mean albumin was 26.3 ± 9.7 g/L. 
FSGS had the lowest mean albumin at 24.3 ± 10.3 g/L, followed very closely by 
MN, MPGN, MCD. IgAN was closest to that of healthy individuals (35-52 g/L at 
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National Health Laboratory Service used by CMJAH). The albumin value used was 
the one stated on the histology request form or the closest value to the renal 
biopsy date. Poor documentation and inadequate records form the majority of the 
undocumented results. Only values for the most common subtypes have been 
shown for purposes of simplicity. Mean albumin values were not significantly 
different amongst the histological subtypes (p = 0.366 on ANOVA).  
 
3.8 Primary glomerular disease and haemoglobin 
Table 3.8.1 Glomerular disease and haemoglobin (Hb) 
 
 
 
 
 
 
A total of 167 results were found for analysis of Hb. The total mean Hb for the 
study was 12.14 ± 2.7 g/dL. Amongst the most common types of primary GN, the 
highest mean Hb was observed in patients diagnosed with MesPGN (13.3 ± 1.54), 
followed by MCD (13.2 ± 2.5), MN (12.78 ± 2.2) g/dL, MPGN (12.0 ± 2.24), FSGS 
(11.59 ± 3.15) and IgAN (9.93 ± 1.45) g/dL respectively. A significant difference in 
Hb was noted amongst the histological subtypes (p = 0.02 ANOVA). Females 
(11.49 ± 2.42) g/dL had a lower mean Hb than males (12.65 ± 2.8) g/dL (p = 0.004 
Chi Square). 
 
Histology N  (Hb) Mean ±  Std dev g/dL 
IgAN 3 9.93 ± 1.45 
FSGS 52 11.59 ± 3.15 
MPGN 33 12.0 ± 2.24 
MN 33 12.79 ± 2.20 
MCD 28 13.2 ± 2.52 
MesPGN 4 13.35 ± 1.54 
   
Gender   
Male 94 12.65 ± 2.8 
Female 69 11.49 ± 2.42 
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3.9 Primary glomerular disease and dyslipidaemia 
Table 3.9.1 Cholesterol and histological subtypes 
 
Histology Cholesterol Cholesterol mmol/l N Mean  ± Std.Dev 
FSGS 45 9.9  ± 5.3 
MCD 23 9.8  ± 4.6 
MN 30 7.7  ± 3.4 
MesPGN 3 7.6  ± 3.9 
MPGN 30 6.2  ± 2.9 
Thin GBM  2 6.0  ± 2.1 
GGS 3 5.1  ± 1.1 
IgAN 2 4.7  ± 2.1 
Total 143 8.2  ± 4.4 
 
A total of 143 values for cholesterol were analysed. In histological subtypes with 
only one patient, the recorded value was omitted from the table. The highest 
cholesterol levels were recorded amongst those with FSGS (9.9 ± 5.3) mmol/l 
followed by MCD (9.8 ± 4.6) mmol/l and MN (7.7  ± 3.4) mmol/l. Cholesterol levels 
tended to be within the normal range for patients diagnosed with Anti-GBM 
Disease, crescentic GN, immunotactoid GN, IgAN and GGS but the sample size in 
these subtypes were small. Measured cholesterol levels were significantly different 
between the histological subtypes (p = 0.022 on ANOVA). 	
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Table 3.9.2 Triacylglycerol (TG) and histological subtypes 
Histology Triacylglycerol mmol/L N Mean (Std.Dev) 
FSGS 40 3.2 ± 2.3 
MesPGN 3 2.9 ± 1.9 
MCD 20 2.7 ± 1.9 
GGS 2 2.6 ± 0.8 
MN 23 2.4 ±1.5 
MPGN 27 1.8 ± 1.3 
IgAN 2 1.6 ± 0.6 
Total 123 2.6 ± 1.9 
 
The highest TG levels were recorded among those patients diagnosed with FSGS 
(3.2 ± 2.3), MesPGN (2.9 ± 1.9), MCD (2.7 ± 1.9), MN (2.4 ± 1.5), and MPGN (1.8 
± 1.3) mmol/L. Subtypes with only one patient were omitted from Table 3.9.2. The 
TG values tended to be in the normal range amongst patients with immunotactoid 
GN, anti GBM, DPGN and IgAN, but these sample sizes were small. ANOVA 
testing did not demonstrate a statistically significant difference in TG levels 
between the various histological subtypes (p = 0.289). 
 
 
3.10 Primary glomerular disease and urine white cell count 
 
 
Table 3.10.1 Urine white cell counts and histological subtypes 
 
Histology UWCC UWCC N 
 
Median [ Interquartile Range] 
 
IgAN 4 115 500 [38 250 – 321 000] 
MPGN 21                               46 000 [12 000 – 117 000] 
FSGS 29                               33 000 [7 000 – 77 000] 
MCD 15                               18 000 [7 500 – 28 000] 
MN 16                               15 500 [6750 – 56 250]  
MesPGN 2                               4 500 [2750 – 6250] 
 
The highest UWCC was observed in patients with IgAN 115 500 [38 250 – 321 
000] followed by those with MPGN 46 000 [12 000 – 117 000], FSGS 33 000 [7 
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000 – 77 000], MCD 18 000 [7 500 – 28 000], MN 15 500 [6750 – 56 250] and 
MesPGN 4 500 [2750 – 6250]. No significant difference in UWCC was noted 
between histological subtypes (p = 0.234 ANOVA). It should be noted that patients 
with values < 1000 or > 750 000 as reported by the NHLS were excluded from this 
analysis. Only histological sub types with more than one record were documented 
on the table above. 
 
3.11 Primary glomerular disease and urine dysmorphic red cells  
 
Table 3.11.1 Urine dysmorphic cells and histological subtypes 
 
Histology 
Urine dysmorphic RC 
Recorded 
No dysmorphic 
cells seen 
Dysmorphic RC (%) 
N N Mean ± Std Dev 
IgAN 5 4 80 
MN 24 20 40 ± 39 
MCD 26 19 34 ± 32 
FSGS 39 21 33 ± 27 
MPGN 21 9 24 ± 16 
ANCA Vasc 1 0 10 
GGS 4 4 - 
MesPGN 3 3 - 
Thin GBM  2 2 -  
DPGN 1 1 - 
Immunotactoid GN 1 1 -  
NV 1 1 -  
 
A total of 128 records for urine dysmorphic red cells were found. 85 patients had 
no dysmorphic red cells seen. Amongst patients with urinary dysmorphic red cells 
seen on microscopy, the highest mean was recorded in patients with IgAN (80%) 
followed by those with MN (40 ± 39), MCD (34 ± 32), FSGS (33 ± 27), and MPGN 
(24 ± 16%). No dysmorphic red cells were seen in MesPGN, DPGN, GGS, 
Immunotactoid GN, NV and thin GBM disease. This result may be skewed due to 
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small patient numbers in these categories. No significant difference in urinary 
dysmorphic red cell percentage was noted between the histological subtypes (p  = 
0.989 ANOVA).  
 
3.12 Primary glomerular disease and urine casts 
Table 3.12.1 Casts and histological subtypes 
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None Observed 20 23 2 14 10 1 4 4 1 0 3 1 1 84 (56.8%) 
 % 23.8 27.4 2.4 16.7 11.9 1.2 4.8 4.8 1.2 0 3.6 1.2 1.2 100% 
Granular 0 9 0 4 4 0 0 0 0 0 0 0 0 17 (11.5%) 
 % 0.0 52.9 0.0 23.5 23.5 0 0 0 0 0 0 0 0 100% 
Granular & 
Hyaline 
5 7 0 4 5 0 0 1 0 1 0 0 0 23 (15.5%) 
 % 21.7 30.4 0 17.4 21.7 0 0 4.4 0 4.4 0 0 0 100% 
Hyaline 4 6 0 3 7 0 0 0 0 0 0 0 0 20(13.5%) 
 % 20 30 0 15 35 0 0 0 0 0 0 0 0 100% 
Total 29 46 4 25 27 1 4 5 1 1 3 1 1 148 
 % 19.6 31.1 2.7 16.9 18.2 0.7 2.7 3.4 0.7 0.7 2.0 0.7 0.7 100% 
 
 
Table 3.12.1 demonstrates the types of urinary cast detected on urinalysis by 
histological category. (56.8%) of patients had no casts observed, (0.6%) had 
cellular, (11.5%) granular, (15.5%) a combination of granular and hyaline, (13.5%) 
hyaline, and (0.7%) granular and waxy combination and (0.7%) red cell casts. 
Granular and waxy combination and red cell casts were found in one patient each 
with MPGN and MesPGN and were not tabulated for purposes of simplicity.  
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For the patients presenting with MN, (69.0%) had no casts, (17.2%) had granular 
and hyaline casts, and (13.8%) had hyaline casts. In patients who presented with 
FSGS, (50%) had no casts, granular (19.6%), granular and hyaline (15.2%), 
hyaline (13%) and (2.2%) had cellular casts observed. Of the patients diagnosed 
with MCD, (56%) had no casts; granular casts were present in (16%), granular and 
hyaline casts were present in (16%), and hyaline casts were present in (12%). 
 
No casts were observed for patients that presented with DPGN, immunotactoid 
GN, thin GBM, Anti-GBM and benign familial haematuria. This is likely as a result 
of the small sample sizes in these subtypes or laboratory error. Urinary casts were 
not significantly different amongst the different histological subtypes (p = 0.155 
Pearson Chi Square). The line graph in Figure 3.12.1 illustrates the frequency of 
casts and histology. 
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Figure 3.12.1 Primary glomerular disease and casts 
 
 
 
 
3.13 Primary glomerular disease and urine protein: creatinine 
 
Table 3.13.1 UPCR and histological subtypes 
 
 
 
 
 
 
 
 
 
 
A total of 158 cases with recorded UPCR were analysed. In histological subtypes 
with only one record, only the actual value is documented on the table as no 
standard deviation was calculated. The highest mean UPCR value was recorded 
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Histology  UPCR N Mean (Std. Dev.) 
Thin GBM  2          2.1 ± 2.1 
MN 35 0.94 ± 0.74 
FSGS 52 0.89 ± 0.66 
MPGN 28 0.66 ± 0.46 
IgAN 3 0.62 ± 0.42 
MCD 26 0.60 ± 0.38 
MesPGN 4          0.4 ± 0.5 
GGS 4          0.2 ± 0.2 
Immunotactoid GN 1 0.7 
Anti-GBM 1 0.4 
DPGN 1 0.3 
ANCA Vasculitis 1 0.1 
Total 158 0.8 ± 0.6 
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among those with MN (0.94 ± 0.74) g/mmol followed by FSGS at (0.89  ± 0.66), 
MPGN (0.66  ± 0.46), IgAN (0.62 ± 0.42) and MCD (0.60 ± 0.38) g/mmol. Analysis 
by ANOVA demonstrated that UPCR was significantly different by histological 
subtype (p = 0.017). This result may be biased in the groups with small patient 
numbers. The differences are illustrated on the means and confidence interval plot 
in Table 3.14.1. 
 
 
3.14 Podocytopathies and biochemical presentation 
 
Table 3.14.1 Histology and biochemical presentation 
 
 
 
 
 
 
The median creatinine value was highest in the FSGS group 183.5 [101 - 476] 
μmol/l, followed by MPGN 156.5 [104 - 239] μmol/l, MN 92.5 [63 - 140] μmol/l; the 
lowest median creatinine value was for MCD79 [65 - 103] μmol/l). These values 
are also seen on the plot of means and confidence intervals in Figure 3.14.1. 
Creatinine levels were significantly different by podocytopathy subtype (p = 0.005 
ANOVA). 
 
 
 
 
Histo 
Creatinine Cholesterol UWCC 
N Median [IQR] N Mean ± 
Std.Dev 
N Median [IQR] 
FSGS 54 183.5 [101 - 476] 45 9.9  ± 5.3 29 33 000 [7 000 – 77 000] 
MPGN 34 156.5 [104 - 239] 30     6.2 ± 2.9 21     46 000 [12 000 – 117 000] 
MN 32 92.5 [63 - 140] 30 7.7  ± 3.4 16     15 500 [6750 – 56 250] 
MCD 29 79 [65 - 103] 23 9.8  ± 4.6 15 18 000 [7 500 – 28 000] 
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Figure 3.14.1 Means and confidence intervals of creatinine 
 
The highest mean cholesterol value was observed for FSGS (9.9 ± 5.3μmol/L), 
followed by MCD (9.8 ± 4.6), MN (7.7 ± 3.4) and the lowest were for MPGN (6.2 ± 
2.9μmol/L). This is also seen on the plot of means and confidence intervals 
showing wide confidence intervals throughout the podocytopathies, Figure 3.14.2. 
Cholesterol varied by histological subtype (p = 0.001 ANOVA). 
 
Figure 3.14.2 Means and confidence intervals of cholesterol 
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The highest UWCC median and IQR was found in MPGN 46 000 [12 000 – 117 
000 followed by FSGS 33 000 [7 000 – 77 000], MCD 18 000 [7 500 – 28 000] and 
MN 15 500 [6750 – 56 250] had the lowest UWCC value. The difference in the 
UWCC by podocytopathy histology was not statistically significant (p-value = 0.132 
ANOVA). 
 
3.15 Primary glomerular disease and blood pressure (BP) 
 
 
Table 3.15.1 Blood pressure and histological subtypes 
 
Histology Hypertension 
Yes No Row Total 
MN 1 1 2 
Row % 50 50 100 
Total % 4.35 4.35 8.7 
FSGS 3 2 5 
Row % 60 40 100 
Total % 13.0 8.7 21.7 
MesPGN 1 1 2 
Row % 50 50 100 
Total % 4.35 4.35 8.7 
MCD 0 6 6 
Row % 0 100 100 
Total % 0 26 26 
MPGN 4 3 7 
Row % 57.1 42.9 100 
Total % 17.4 13 30.4 
Immunotactoid GN 0 1 1 
Row % 0 100 100 
Total % 0 4.35 4.35 
Totals 9 14 23 
Total % 39.1% 60.9% 100% 
 
 
23 records for BP were found. 39.1% of patients had hypertension at the time of 
biopsy. None of the patients biopsy-proven MCD had hypertension. The highest 
frequency of hypertension was observed in the MPGN group. 60% of patients with 
FSGS had hypertension. There is no significant difference between hypertension 
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and histological sub-types (p = 0.969 by Pearson Chi square). This is likely due to 
the very small sample size as a result of inadequate documentation of BP. 
 
3.16 Primary glomerular disease patterns over time 
 
Figure 3.16.1 Histological subtypes by years 	
 
 
The results show that 5.5% of the patients had their biopsy done in 2001, 5.5% in 
2002, 4.9% in 2003, 12.8% in 2004, 13.4% in 2005, 9.8% in 2006, 14.6% in 2007, 
15.9% in 2008, 7.7% in 2009, and 9.8% in 2010. The most biopsies were done in 
2008. It was noted that MN had the highest frequency during the periods 2001 to 
2002, then FSGS dominated in the period 2003 to 2007. In 2008 MPGN was the 
most prominant type. In 2009 it was MPGN and MCD and in 2010 the highest 
frequency was for FSGS and MCD. The distribution of podoctyopathy histology 
over the years is statistically significant Pearson Chi-square p-value = 0.01. This is 
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also noted on the frequency plot Figure 3.16.2 that shows that FSGS is amongst 
the most common subtypes in most years, however there is no discernable trend. 
 
Figure 3.16.2 Podocytopathies over time 
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4. DISCUSSION 
4.1 Overview of records 
A total of 1495 renal biopsies were done at Charlotte Maxeke Johannesburg 
Hospital between 1 January 2001 and 31 December 2010. 1135 biopsies were 
excluded from analysis at initial record review for the following reasons: 
• Patients under 18 years 
• Transplant kidney biopsies 
• Patients diagnosed with HIV  
• Insufficient records available for analysis of clinical and biochemical data  
 
The incidence of primary glomerular disease (53.8%) was higher than that of the 
secondary (40.2%) and non-glomerular pathologies (5.8%).  
In 2014 at Chris Hani Baragwanath Hospital (CHBAH), the incidence of primary 
glomerular disease was found to be (39.7%) and secondary (49.3%)44. In Cape 
Town in 2001-2009, a similar time line to this study, the incidence of primary and 
secondary glomerular disease was found to be (31.2%) and (49.0%) respectively, 
which is similar to the results at CHBAH28. 
 
In the current study patients that were HIV positive were excluded at initial review, 
and this may play some part in the lower numbers for secondary glomerular 
disease, as HIV is an ubiquitous infectious agent in South Africa and a well 
documented cause of glomerular disease. This result may also be skewed by local 
biopsy practices, which eschew biopsy in cases of clear diabetic and hypertensive 
nephropathy, and biopsy is usually performed in patients with unclear diagnosis. 
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Hence the rate of secondary pathologies may be under reported. Patients with 
lupus nephritis (LN) were excluded from the primary disease cohort after 
confirmation on renal histology.  
The most common secondary cause of glomerular disease in the current study 
was LN (55.8%) followed by hypertensive nephrosclerosis (16.5%), diabetic 
nephropathy (9.6%) and post-infectious GN (6.8%). 	
The high incidence of LN as the most common secondary GN worldwide has been 
extensively documented. Recent data include CHBAH in 2014 (31%), Cape Town 
in 2011 (39%), Oman in 2013 (36.1%), China in 2012 (53.2%) and Brazil in 2010 
(45.5%) 44,28,47,48,34. The above data supports this study. CMJAH is a referral 
hospital for SLE patients and intensive monitoring of patients is practiced as renal 
involvement is independently associated with poor outcome49, hence the early 
detection rate and high referral for renal biopsy, which generally alters treatment 
protocols. 
4.2  Glomerular disease by indication to biopsy 
The most common indications for biopsy in primary glomerular disease were 
nephrotic range proteinuria (60.53%) followed by unexplained renal dysfunction 
(24.2%), a combination of nephrotic / nepritic features (8.4%), sub nephrotic range 
proteinuria (3.2%) and abnormal urinary sediment (2.6%). 
 
Nephrotic range proteinuria is overwhelmingly the most common indication for 
biopsy in this study. These results have been echoed in other studies in South 
Africa, Africa, and the rest of the world. There are however contrasting studies 
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where abnormal urine findings, renal dysfunction and nephritic syndrome are more 
prominent. These differences are multifactorial in aetiology. Indication to biopsy is 
under influence of geographic location, expected histological outcomes, biopsy 
practices in different regions, clinical skills, experience of nephrologists and 
financial constraints. Environmental factors, genetics and infections may also play 
a role. 
Table 4.2.1 Nephrotic syndrome as the most common indication for biopsy 
Area  Year of study Frequency Reference 
Johannesburg 2001- 2010 59.2 % Current study 
Johannesburg 1982 - 2011 47.7 % 44 
Cape Town  2000 - 2009 52.5 % 28 
Bloemfontein 1997 - 2006 unknown 27 
Senegal 1993 - 1998 67 % 50 
Morocco  2000 - 2007 60.3 % 51 
China 2000 -2010 52.5 % 48 
Pakistan 1995 - 2008 49.9 % 52 
India 1990 - 2008 49 % 43 
Sudan  2010 - 2011 46.5 % 31 
Brazil 1993 - 2007 39 % 34 
Spain 1994 - 1999 35.2 % 53 
Egypt 1998 - 1999 31.9 % 54 
 
Table 4.2.2 Non nephrotic indications for biopsy 
Area  Year of study Indication for bx Frequency Reference 
Belgium 1991 - 2006 Urinary abnormalities 53.5 % 55 
Finland  1976 - 2000 Urinary abnormalities 38.7 % 56 
Italy 1996 - 2000 Urinary abnormalities 53.2 % 57 
France 1976 - 2002    CKD 36 % 58 
Japan 2007 - 2008 Nephritic syndrome 48.2 % 59 
 
Nephrotic range proteinuria was the most common indication for biopsy in patients 
subsequently diagnosed with MN (89.1%), FSGS (66.6%), MCD (69.7%), 
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MesPGN (60%), MPGN (40%). Unexplained renal dysfunction was the most 
common indication for biopsy in patients subsequently diagnosed with IgAN 
(66.6%). These findings are consistent with the clinical presentation of non-
proliferative disorders like MN, FSGS and MCD, which usually present with 
nephrotic features and proliferative disorders such as IgAN which usually present 
with haematuria / nephritic features, renal dysfunction or nephrotic syndrome.  
 
4.3 Most frequent primary histological pattern 
FSGS (29.8%) was found to be the most common cause of primary glomerular 
disease in this study followed by MN (19.5%) and MPGN (18%), MCD (17%), IgAN 
(3%) and MesPGN (3%). This trend mirrors previous studies undertaken in SA and 
other parts of the developing world. This may be due to the higher incidence of 
non-proliferative GN especially FSGS in developing worlds compared to 
proliferative IgAN first world countries. Genetic factors involving APOL 1 / MYHC 9  
gene penetrance in black patients and a second hit being poor nephron mass 
especially in low socio economic settings like ours are contributing factors.  
Table 4.3.1 FSGS as the most frequent primary glomerulopathy 
Area  Year of study Frequency Reference 
Johannesburg 2001- 2010 29.8 % Current study 
Johannesburg 1982 - 2011 29 % 44 
Bloemfontein 1997 - 2006 unknown 27 
Senegal 1993 - 1998 47 % 50 
Columbia  1998 - 2007 37.7 % 60 
Belgium 1991 - 2006 30.3 % 55 
Sudan  2010 - 2011 29.6% 31 
Pakistan 1995 - 2008 29 % 52 
Brazil 1993 - 2007 24 % 34 
Egypt 1998 - 1999 22.6 % 54 
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This may be in part reflective of local practice, which considers isolated 
haematuria an indication for renal biopsy, and good urinary surveillance1 with urine 
dipstix and blood pressure monitoring. Diseases that present with isolated 
haematuria are more likely to be asymptomatic in comparison with gross clinical 
features with nephrotic syndrome. Doctors and nephrologists in various parts of 
the world are also aware of the most common histological variants in their 
geographic location, and surveillance and biopsy practice is likely based on these 
patterns. Studies confirming this have been done in Europe, America and 
Australia. 
 
Table 4.3.2 Non FSGS most frequent primary glomerular disease 
Area  Year of study Histology Frequency Reference 
France 1976-2002 IgAN 73.4 % 58 
Ireland  1976 - 2005 IgAN 38.8% 1 
Finland  1976 - 2000 IgAN 34.9% 56 
Italy 1996 - 2000 IgAN 34.5% 57 
Australia 1995 - 1997 IgAN 34.1 % 61 
Korea 1987 - 2006 IgAN 28.3 % 62 
Japan 2007 - 2008 IgAN 27.6 % 59 
USA 1974 - 2003 IgAN 22 % 35 
Spain 1994 - 1999 IgAN 17.2 % 53 
Cape Town  2000 - 2009 MPGN 20.4 % 28 
Morocco  2000 - 2007 MCD 26 % 51 
India 1990 - 2008 MCD 21.8 % 43 
China 2000 - 2010 MN 31.7 % 48 
Iran 1998 - 2007 MN 26.8 % 63 
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In developing worlds like SA, the increased incidence of FSGS may be as a result 
of the aggressive nature of the clinical presentation i.e. gross oedema and renal 
derangement in FSGS likely prompting more urgent investigation and referral for 
biopsy than the patients presenting with isolated haematuria. CMJAH is a public 
centre tertiary hospital hence the patient population is usually from the lower 
income sector. These patients do not have medical insurance and are required to 
attend their primary health care facility and then be referred to a secondary level 
hospital prior to being referred to a tertiary or quartenary level hospital for 
consideration of biopsy. Delays occur at most levels due to late presentation of 
patients, poor resources, referral systems and transport issues.  
 
Although patients with HIV were excluded from this study, to not mention the high 
burden of disease in SA would be an oversight. In resource limited settings renal 
biopsy is usually limited to the more acute patients, those requiring diagnosis and 
patients in whom prompt intervention is required. There is a high incidence of HIV 
infection in SA and this predisposes patients to a more aggressive form of 
secondary FSGS. The late presentation of patients at our center, delayed referral 
from some peripheral care facilities and poor surveillance of urinary sediment may 
also play a role in the frequency of FSGS in this study. 
 
Other postulations include underlying genetic factors like APOL 1 and MYHC 9 
gene, which has been found to be a risk factor for the development of FSGS. 
These alleles are present in patients of African descent and their family members 
and absent from their Caucasian counterparts20,21. 
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The underlying population at CMJAH is predominantly from African origin. Further 
evidence for genetic variation is found in a 30 year retrospective review in Ireland, 
in an over 99% Caucasian population documenting a 49% incidence in IgAN1. 
 
In 1988, Brenner proposed that babies born with low birth weight or intra uterine 
growth retardation had an increased susceptibility to hypertension, reduced 
sodium excretory capacity, progressive renal insufficiency and chronic kidney 
disease64. This may be a risk factor for the development of FSGS considering that 
in 2013, Statistics South Africa reported that 53.9% of babies were born with low 
birth weights less than 2500g 65. Patients born with low birth weight are also more 
common amongst the lower socio economic income groups and African origin in 
South Africa due to previous political injustices, and many of these patients access 
state hospitals like CMJAH more frequently. 
 
4.4 Primary glomerular disease and gender 
 
There was an overall male preponderance, 59.5% vs females 40.5%.  This male 
dominance is mainly as a result of FSGS, MPGN and IgAN as a similar male to 
female ratio was noted in the MN, MCD and MesPGN. According to statistics SA, 
there is a fairly equal distribution in gender in Johannesburg with 50.2% males65. 
The results in this study echo a very large study in Brazil reviewing 9617 renal 
biopsies over 15 years showing a 54% overall male predominance in primary 
glomerular disease34. 
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4.5 Primary glomerular disease and ethnicity 
 
The majority of all patients biopsied were of black ethnicity (73.9%), followed by 
white (16.1%) and indian (8.3%) patients. This distribution of ethnic variation 
reflects the population base at CMJAH, which is a state facility. The trend also 
mirrors the numbers quoted by Statistics SA in 2013 with (79.8%) of Gauteng 
being of black African descent, (8.9%) coloured, (8.7%) white and (2.6%) Indian65. 
 
The percentage black vs white patients with FSGS, MCD, MPGN MN and 
MesPGN, were 30.2% vs. 25.8%, 19% vs 12.9%, 20.4% vs 6.4% 19.1% vs. 19.5% 
and 3.5% vs. 3.2% respectively. The black to non-black ratios amongst the 
podocytopathies were MPGN (85.3% vs 14.7%), and MCD (81.8 vs 18.2%), FSGS 
(75.4% vs 24.6%), and MN (71% vs 29%). There is likely some selection bias as 
the study population was predominantly of black ethnicity and most histological 
subtypes had more patients in the black ethnic group. There was no statistical 
significance in the distribution of histological patterns between the ethnic groups (p 
= 0.242). 
 
In Cape Town between 2000 – 2009, a similar time line to the current study, 
mesangiocapillary / MPGN was found to be the most common primary glomerular 
disease (20.4%) 28. The percentage black vs white patients for MPGN, MesPGN, 
MN, FSGS and MCD were (20.6% vs 16.7%), (17.7% vs 27.8%), (16% vs 22%), 
(13.1% vs 5.6%), (6.3% vs 5.6%) respectively. Mixed ancestry patients who 
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formed the majority were documented separately. These results were not 
statistically significant. 
 
Ethnic variation is important in susceptibility for glomerular subtypes. There is 
substantial evidence that an African population is at higher risk for primary and 
secondary FSGS due to multiple variables including hypertension, diabetes, HIV, 
and genetic risk. Our study showed FSGS to be the most common type in a largely 
African population. In a study looking at APOL genotype amongst patients of 
different ethnic groups, a recessive model conferred a 17 fold higher odds for 
patients with the APOL variant and FSGS.  FSGS associated with the APOL risk 
alleles were also associated with a younger age of onset and faster progression to 
renal failure66. Further evidence for genetic variation and histological subtypes is 
found in a 30 year retrospective review in Ireland in an over 99% Caucasian 
population documenting a 49% incidence in IgAN1. Pure genetics is not enough to 
cause FSGS and it is likely a second hit hypothesis may be involved especially 
after reviewing the results of the current study. 
 
4.6 Primary glomerular disease and age groups 
 
The majority of patients were in the 18-40 year old age group (62.89%), followed 
by the 40-60 year subgroup (24.74%); the least number of patients were from the 
above 60year old age group (12.37%). This is consistent with published data 
showing that primary glomerular pathology is more common amongst younger 
patients.  
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The most frequent histological subtype in the 18 – 40 age group was FSGS 
(30.3%), in the 40 – 60 year old sub group and above 60 year old subgroup, MN 
was most frequent at (27.1% and 41.7%) respectively. 
 
Age groups between the primary glomerular pathologies from the recent study in 
Johannesburg at Chris Hani Baragwanath Hospital found similar results to this 
study. FSGS and MN were the most common subtypes in patients aged 20 – 39 
years, 40 – 59 years and above 60 years44. 
 
A large Indian study reviewing 1849 patients confirmed the above results showing 
a mean age of 32.77 years. This Indian study also documented the mean age for 
FSGS, MCD, MPGN and MN to be 25, 26, 27 and 40 years respectively, 
highlighting the younger age of presentation for the first three and the slightly older 
age of presentation of MN43. In the current study, most patients over 60 years 
presented with MN (41.67%).  The peak incidence of MN is known to be 40- 50 
years old12.  
 
4.7 Primary glomerular disease and biochemical parameters 
Amongst the commoner subtypes, the highest median and IQR for creatinine were 
recorded in patients diagnosed with IgAN 488 [315 - 694] μmol/l followed by FSGS 
183.5 [101 - 476] μmol/l, MPGN 156.5 [104 - 239], MN 92.5 [63 - 140], MCD 79 
[65 - 103] and MesPGN 76 [66 - 177.5] μmol/l). A significant difference was noted 
in the mean creatinine amongst the histological subtypes (p < 0.001 Kruskall - 
Wallis). 
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The median and IQR for eGFR amongst the podocyopathies FSGS, MPGN, MN, 
MCD were 40.9 [12.6 – 86.9], 57.4 [30.6 – 77.9], 85.4 [50.6 – 131.5], 111.7 [79.9 – 
137.8] mL/min/1.73m2 respectively. The highest median eGFR was found in MCD 
111.7 mL/min/1.73m2 which is more than twice FSGS 40.9 mL/min/1.73m2. The 
severity of renal dysfunction at presentation is different between the histological 
subtypes (p < 0.001 Kruskall - Wallis). 
 
Renal insufficiency is known to be common at presentation with FSGS, occurring 
in about 30-45% of cases; the level of serum creatinine at biopsy is also predictive 
of progression to ESRD67. The mean eGFR at presentation of MCD patients is 
usually preserved or slightly deranged unless poor prognostic features like 
advanced age, hypertension or extremes in albumin or proteinuria is present68. 
Other causes of renal dysfunction in MCD are pre renal azotaemia due to 
intravascular contraction from hypoalbuminaemia, renal vessel thrombosis, over 
diuresis, nephrotoxins and intra renal parenchymal oedema.  
 
A Chinese study69 evaluating the metabolomics (quantitative measurement of the 
dynamic multi parametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification) of primary GN in 2013 found 
that the mean eGFR was reduced in GN versus healthy participants in whom the 
mean eGFR was 120mL/min/1.73m2. The most affected was FSGS 94 ± 33.1, 
followed by IgAN 99 ± 22.3, MCD 101 ± 32.4 and MN 108 ± 45.3 ml/min/1.7m2 .  
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The GN progress trial reviewed 339 white patients in Paris, and recorded the 
eGFR median and IQR of FSGS 56 [36-83], IgAN 70 [42-92], MN 79 [61-95] 
mL/min/1.73m2  70. The values for FSGS are similar to the Chinese and the current 
study, which also highlights the severity of renal dysfunction in FSGS compared to 
the other GN due its underlying physiology irrespective of ethnicity. Of note, is that 
in the GN progress trial, all patients with eGFR <15 ml/min/1.73m2  were excluded.  
 
All these studies show greater derangement in eGFR for FSGS with more 
preserved levels for MN and MCD. These results support the findings in the 
current study. Similar values were seen in MN and MCD in my study and the 
Chinese study. FSGS is known to have greater renal impairment at presentation 
compared to the fairly well preserved renal function of MCD and MN, this is known 
and is due to the basic underlying pathophysiology of each disease process. 
 
Amongst the podocytopathies, FSGS had the lowest mean albumin at 24.3 ± 10.2 
g/L, followed closely by MN, MPGN, MCD (24.5 ± 9.8, 24.8 ±7.1, 26.2 ± 9.4 g/L) 
respectively. Mean albumin in IgAN 32.5 ± 14.8 was closest to that of healthy 
individuals, although these observations did not reach statistical significance (p = 
0.366). This current study correlated closely to the study in China mentioned 
above which showed the mean albumin levels for MN, MCD and IGAN to be (20 ± 
7.21, 23 ± 11.2, 34.9 ± 4.67g/L), The mean albumin for FSGS (36.05 ± 7.76g/L) 
however was higher in China69. This difference may in part be due to later 
presentation, delayed referral for biopsy in our setting, a more aggressive type of 
FSGS and differences in dietary protein intake. 
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In the current study, amongst the most common types of primary 
glomerulopathies, the highest mean Hb was observed in patients diagnosed with 
MesPGN (13.3 ± 1.54), followed by MCD (913.2 ± 2.5) followed by MN (12.7 ± 2.2) 
g/dL, MPGN (12.0 ± 2.2), FSGS (11.6 ± 3.1) and (IgAN 9.93 ± 1.45) g/dl 
respectively. Males had a higher mean Hb (12.65 ± 2.82) compared to females 
(11.4 ± 2.4) g/dL. 
 
The GN PROGRESS trial in 2008 reviewed clinical and biochemical data in 536 
patients with FSGS, MN or IgAN. The mean Hb amongst women in FSGS, IgAN 
and MN were (12.6 ± 1.6, 12.3 ± 1.4, 12.0 ± 1.5 respectively) 70. The mean Hb 
amongst men was approximately 1.5 g/dL higher in each category. This result 
supports the results in my study and it is well known that males have a mean Hb 
about 12% higher than their female counterparts71. These results are comparative 
to the results in the current study, except that the Hb for IgAN was lower in the 
current study. These patients with IgAN also presented with the lowest eGFR and 
low Hb’s which may be as a result of the renal dysfunction or later presentation. 
 
The highest cholesterol levels were recorded in those patients with non-
proliferative glomerular pathology FSGS (9.9 ± 5.3) mmol/L, MCD (9.8 ± 4.5) and 
MN (7.7 ± 3.4) followed by proliferative MPGN and IgAN (6.15 ± 2.8), (4.65 ± 2.0) 
mmol/L respectively with a significant p-value of 0.022. 
  
These findings correlate with the Chinese study reviewing 89 patients with primary 
GN, which demonstrated an elevated total cholesterol and range amongst MCD 
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9.62 [3.9-13.9mmol/L] and MN 7.3 [3.3-14.5mmol/L/]; interestingly, the cholesterol 
levels in FSGS 5.2 [8-10mmol/L] in the Chinese study were lower than those seen 
in the CMJAH cohort69. 
 
A Saudi Arabian retrospective review of 120 patients with primary GN found a 
mean total cholesterol of 5.9 ± 1.4 72, which is lower than that of this study (8.2 ± 
4.4) mmol/L. The difference was mainly due to higher FSGS and MN in our study 
(9.9 ± 5.3 and 7.7 ± 3.4 vs 5.6 ± 1.2 and 5.4 ± 1.2 mmol/ L). The values for MCD 
and IgAN 8.0 ± 3.3, 6.0 ± 1.6mmol/L respectively were similar. This is again likely 
due to late presentation and hence increased severity of disease on presentation 
and probably more aggressive underlying disease. It is also interesting to note, 
that in the current study, the non-proliferative GN being FSGS, MCD and MN had 
the highest total cholesterol and the lowest albumin levels. These clinical 
parameters are linked to the underlying disease process and the nephrotic 
syndrome presentation.  
 
The mean triacylglycerol (TG) level for the 123 records was (2.6 ± 1.9)mmol/L. 
Amongst the most frequent GN, the highest levels were recorded among those 
with FSGS (3.2 ± 2.3)mmol/L followed by MesPGN (2.9 ± 1.8)mmol/L, MCD (2.7 
±1.9) mmol/L, MN (2.4 ± 1.4)mmol/L, MPGN (1.8 ± 1.2)mmol/L with IgAN having 
the lowest TG levels (1.6 ± 0.5)mmol/L. There were no significant differences in 
the mean TG values among the histological subtypes (p = 0.289).  These results 
are similar to the findings of the Chinese study discussed above, FSGS 2.2 [0.5-
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5.5]mmol/L, MCD 2.6[1.0- 7.4], MN 2.4[0.8-2.5] and IgAN 1.2[0.5-8.2]mmol/L. The 
Saudi Arabian study mentioned above recorded a mean TG of 3.5 ± 1.1 mmol/L72. 
 
These studies support this current study in that non-proliferative glomerular 
disease was associated with more severely aberrant dyslipidaemia than 
proliferative glomerular disease, consistent with the established pathophysiology 
of the nephrotic syndrome as discussed above69. 
 
4.8 Primary Glomerular Disease And Urinary Parameters 
The highest UWCC was observed in patients with IgAN 115 500 [38 250 – 321 
000] followed by those with MPGN 46 000 [12 000 – 117 000], FSGS 33 000 [7 
000 – 77 000], MCD 18 000 [7 500 – 28 000], MN 15 500 [6750 – 56 250] and 
MesPGN 4 500 [2750 – 6250]. No significant difference in UWCC was noted 
between histological subtypes (p = 0.234 ANOVA). 
 
An Italian study from 1999-2002, reviewing 100 patients with proliferative and non-
proliferative GN reviewed several urinary parameters. They noted that the number 
of urine leucocytes correlated with intra and extra capillary glomerular proliferation 
and that patients with leucocytes and red cells in urine, had an odds ratio of 7.85 
and 4.33 respectively of having a proliferative GN73. This supports this current 
study, which shows high levels of urinary white cells in IgAN and MPGN. 
 
The highest mean urinary dysmorphic red cell was recorded in patients with IgAN 
(80%) followed by those with MN (40 ± 39), MCD (34 ± 32), FSGS (33 ± 27) and 
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MPGN (24 ± 16%). Dysmorphic red cells more than 80% are usually glomerular in 
origin74. It is known that proliferative GN presents with urinary red cells and red cell 
casts more frequently than non-proliferative GN75. In the current study no 
significant difference in urinary dysmorphic cell percentage was noted between the 
histological subtypes (p  = 0.989). Small sample sizes may have contributed to this 
 
It was noted that 56.8% of patients in this series had no urinary casts present; 
whilst 15.5% had a combination of Granular and Hyaline, (13.5%) Hyaline, 
(11.5%) granular, (0.7%) Granular & Waxy, (0.7%) Red Cell Casts and (0.6%) had 
Cellular casts. Red cell casts are virtually pathognomonic for glomerular disease74, 
however there was no significant association between casts and primary 
glomerular disease in this study.  The study in Italy mentioned above, showed the 
presence of red cell casts in proliferative glomerular disease to be 84.6% vs 39.6% 
in non-proliferative glomerular disease and patients with red cells in the urine had 
an odds ratio of 9.91 of having an underlying proliferative GN73.  
 
A total of 158 values for UPCR were analyzed. The highest mean UPCR value 
was recorded in patients with FSGS at (0.89 ± 0.66) g/mmol, followed in 
descending order by MN (0.94 ± 0.74), MPGN (0.66  ± 0.46), IgAN (0.62 ± 0.42) 
and MCD at (0.60 ± 0.38) g/mmol (p = 0.01). A preponderance of nephrotic range 
proteinuria was noted, in keeping with the frequency of non-proliferative glomerular 
disease / podocytopathies in this cohort. The GN PROGRESS trial reported 
proteinuria as median and interquartile ranges with the highest being MN 0.54 
[0.21- 0.81] followed by FSGS 0.34 [0.18-0.6] and IgAN 0.11 [0.05-0.22] 70. The 
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Chinese study found the highest levels of proteinuria to be present in MCD 4849 
mg /24hr urine, followed by MN 3155mg /24hr, IgAN 1171mg /24hr and lastly 
FSGS 1095 mg /24hr urine. The lower levels of proteinuria in the Chinese study 
may be due to the inclusion criteria of patients with CKD stage 1 – IV only. This 
excluded patients with end stage renal failure and likely contributes to lower levels 
of proteinuria especially in FSGS compared to the current study69. These findings 
may also support the possibility of a more aggressive type of FSGS in Africa. 
 
Adults with primary FSGS present with nephrotic range proteinuria in more than 
70% of cases. It is known that the degree of proteinuria has prognostic 
significance and patients with non-nephrotic proteinuria have extremely good 
prognosis67.  
 
Nephrotic syndrome, including nephrotic-range proteinuria, is classically a 
manifestation of the non-proliferative glomerular diseases (MCD, FSGS, MN) and 
is rare in proliferative GN types such as IgAN and MPGN. Possible reasons for the 
high proteinuria in IgAN and MPGN in this study include a high incidence of renal 
dysfunction with more proteinuria, more aggressive disease and later presentation. 
It will be interesting to review the biochemistry in the different histological subtypes 
amongst FSGS and IgAN as this likely also plays a part in clinical presentation. 
 
4.9 Primary glomerular disease and blood pressure (BP) 
It was noted that 39.1% of the patients had hypertension with a BP of > 140/90 
mmHg. None of the patients with MCD had hypertension. MCD usually presents 
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as nephrotic syndrome, and hypertension is more frequent in nephritic syndrome. 
Hypertension however, may occur in nephrotic syndrome due to fluid overload or 
renal dysfunction. No significant difference in the presence of hypertension across 
the histological patterns of glomerular disease was present on Chi-square testing 
(p = 0.969). This could be due to the low numbers of patients that had documented 
blood pressures.  
 
These results are supported by a study in China in 2013, where most patients 
were also normotensive and the mean recordings for BP were MCD 125 ± 12 
mmHg, IgAN 124 ± 13 mmHg and FSGS at 20 ± 12 mmHg69. The GN 
PROGRESS trial reviewed patients with FSGS, IgAN, and MN and found a total of 
34% to be hypertensive (> 140/90 mmHg) with a significant p < 0.01 70. Even 
though the patient numbers in my study were low, the frequency of hypertension 
correlated with the aforementioned studies. 
 
4.10 Primary glomerular disease patterns over time 
It was noted that MN had the highest frequency during the periods 2001 to 2002, 
then FSGS dominated in the period 2003 to 2007. In 2008 MPGN was the most 
prominent type. In 2009 it was MPGN and MCD and in 2010 the highest frequency 
was for FSGS and MCD. This highlights the high frequency of FSGS compared to 
IgAN over the study duration. It was noted that FSGS was amongst the most 
common subtypes in each year. Although Chi squared testing showed a 
statistically significant difference in the frequency of histological subtype by year, 
there was no discernable trend in terms of increasing frequency of subtypes.   
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5. CONCLUSION 
The most frequent primary GN was FSGS (29.8%) followed by MN (19.5%), 
MPGN (18%), MCD (17%) and IgAN (3%). Nephrotic range proteinuria (60.5%) 
and unexplained renal dysfunction (24.2%) were the most common indications for 
biopsy.  
 
There was a 59.4% male predominance. (73.9%) of patients were of African 
descent. The majority of patients (62.9%) were from the 18-49 year age group. 
The mean albumin was (26 ± 9.7) g/L, haemoglobin (12.14 ± 2.7) g/dL, cholesterol 
(8.2 ± 4.4) mmol/L, triglyceride (2.6 ± 1.9) mmol/L and urine PCR (0.8 ± 0.6) 
g/mmol. The highest median creatinine was found in FSGS 183.5 [101 - 476]. The 
highest urine leucocytes and dysmorphic red cells were from IgAN. Most patients 
(56.8%) had no casts observed, and (39.1%) were hypertensive.  
 
Glomerular disease is a highly prevalent complex condition with a wide range of 
clinical features that present clinicians with a diagnostic dilemma. Renal biopsy 
has been a crucial innovation in the field of nephrology. This study aimed to review 
the incidence of different types of glomerular disease and the various demographic 
and clinical presentations in relation to indication for biopsy. This study was helpful 
in reviewing mean biochemical and urinary features of primary glomerular disease.  
It is hoped that this study will spark interest in glomerular disease and will serve as 
impetus for future studies, including those with genetic variables, as this will be 
extremely interesting.  
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6. STUDY LIMITATIONS AND STRENGTHS 
6.1 Study Limitations  
1. Lack of adequately / sufficiently recorded data pertaining to the clinical 
presentation parameters discussed in section 2.9 resulted in much smaller 
numbers for analysis than was predicted. 
2. Inability to retrospectively validate contemporary clinical data thus leading to 
bias. 
3. Lack of adequately recorded indications for renal biopsy. 
4. A larger than expected prevalence of secondary causes of glomerular disease 
resulted in decreased numbers for analysis.  
5. Disparity in sample size of the frequent and infrequent histological subtypes. 
Small sample sizes carry inherent risks of bias and inaccuracy but are 
accounted for in statistical methodology. 
 
The following methods and processes were implemented to try to compensate for 
the above factors: 
1. Only those patients in whom histological diagnosis and sufficient clinical 
parameters at the time of biopsy were included. 
2. In cases where data was incomplete, a review of the electronic records at the 
head office of the National Health Laboratory Service (NHLS) was made.  
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6.2 Study Strengths 
1. A large number of cases of primary GN were nevertheless included in this 
analysis (n = 194) 
2. The biochemical and patient demographic parameters between the various 
GN subtypes are objective in nature and not dependent on the subjective 
opinion of the attending doctor at the time of diagnosis 
3. All data included in this study was reviewed by a specialist histopathologist 
and nephrologist 
4. The study duration of 10 years provided a long term analysis of trends. 
 
6.3 Future Studies 
1. Further studies of a similar nature with larger sample sizes and at multiple 
institutions in South Africa are required to substantiate or refute the findings 
of this study.  
2. Given the small group of patients in this case series, many findings were 
not statistically significant; it would be valuable to determine if observed 
trends in this study would constitute significant findings in a larger 
population. 
3. A renal biopsy registry, documenting the indication and result would be 
useful in the South African setting.  
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APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Data Collection Sheet - PRIMARY GLOMERULAR DISEASE 
 
Patient reference number    
Age                     Blood pressure   
Sex   Male      Female     
Race   White     Coloured        Indian       Black          Asian  
 
Indication for biopsy 
Nephrotic range proteinuria  
Sub nephrotic range proteinuria  
Nephritic features                 
Nephrotic / nephritic features         
Abnormal urinary sediment  
Unexplained renal dysfunction  
Lupus nephritis                                
 
Serum Parameters at biopsy 
 
Creatinine                            eGFR                                        WCC   
  
Cholesterol                        Triglyceride                               ANA 
 
Albumin                                           hB         
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Urine parameters        
White cell count    Dysmorphic red cell   
Protein: creatinine ratio 
 
Urine casts 
Hyaline casts         White cell casts   
Red cell casts                             Granular casts  
Waxy casts                 Other    
 
Other 
SLE      DM    HT   HIV  HBV  HCV  
Biopsy findings 
Ig A Nephropathy                        
Minimal Change Disease               
Focal Segmental Glomerulosclerosis       
Membranous Nephropathy              
Membranoproliferative GN                      	
Crescentic GN                                         	
Idiopathic diffuse proliferative GN            
Mesangial proliferative GN             
Interstitial nephritis                                  
Acute tubular necrosis            	
Other                                                       
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